This document provides guidelines for the diagnosis, treatment, prevention and control of dengue. It is a joint publication between the World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases. The document contains 6 chapters that cover the epidemiology and burden of dengue disease, clinical management and delivery of clinical services, vector management and delivery of vector control services, laboratory diagnosis and diagnostic tests, surveillance, emergency preparedness and response, and new avenues for dengue vaccines and antiviral drugs. It is intended to provide up-to-date guidance for professionals on managing dengue cases and preventing transmission.
This document provides information on Dengue fever, including:
1) It is caused by Dengue virus which has 4 serotypes transmitted by Aedes mosquitoes.
2) It progresses through 3 phases: febrile, critical, and recovery. The critical phase can involve warning signs like severe bleeding.
3) Diagnosis is based on symptoms and lab tests showing thrombocytopenia. There is no vaccine or specific treatment, only supportive care.
4) Management involves monitoring for warning signs and providing intravenous fluids and blood products if needed to prevent shock. The goal is early detection and treatment of complications.
This document discusses fluid treatment choices for dengue infection. It begins with an overview of dengue classification and pathophysiology. It then reviews several randomized controlled trials comparing crystalloid and colloid fluid treatments for dengue shock syndrome. The trials found that most patients can be successfully treated with crystalloids alone. For more severe cases, colloids may provide initial volume expansion but have a higher risk of allergic reactions. The document concludes that crystalloids are usually sufficient but colloids may be considered based on individual circumstances.
This document discusses dengue fever, caused by the Aedes mosquito. It notes that dengue illness predominantly affects pediatric populations and can have a high mortality rate. Clinical presentation can vary widely, from fever to bleeding to shock. The disease progresses through febrile, leaky, and congestive phases. Diagnosis involves clinical observation, hematological tests, and virological methods. Management is supportive through monitoring and intervening early if warning signs appear. Prognosis is favorable with early recognition and treatment of plasma leakage and thrombocytopenia. Prevention focuses on eliminating mosquito breeding sites and preventing bites.
This review article discusses autoimmunity in dengue pathogenesis. It suggests that in addition to direct viral effects, immunopathogenesis, including aberrant immune activation and autoantibodies, plays a role in the development of severe dengue disease. Autoantibodies against endothelial cells, platelets, and coagulation molecules induced by dengue virus infection may lead to abnormal activation or dysfunction of these cells and molecules. Molecular mimicry, where dengue virus proteins mimic host proteins, could explain the cross-reactivity of autoantibodies induced during dengue virus infection. Understanding immunopathogenic mechanisms is important for developing a safe and effective dengue vaccine.
MedicYatra provides the safe & best DENGUE Fever treatment and procedure at its affiliate & trusted hospitals & clinics in various metro cities of India, like Mumbai, Delhi, Bangalore, Chennai, Pune etc.Our Associate Board certified doctors are extensively trained and vastly experienced and have performed hundreds of such cases at our state of the art JCI accredited hospitals & Clinics. Our aim is to provide you the best of the services at the most affordable costs. Don't forget to say hi at info@medicyatra.com
Dengue fever is a prevalent mosquito-borne illness caused by dengue virus and transmitted by Aedes aegypti mosquitoes. It affects over 100 countries and causes 50-100 million infections annually. The disease presentation varies from a nonspecific viral syndrome to severe dengue hemorrhagic fever/dengue shock syndrome. There is no vaccine currently available and treatment involves supportive care, with careful fluid management needed for severe cases to prevent shock. Prevention relies on personal protection from mosquito bites and reducing mosquito breeding sites.
This document discusses dengue in children, including its epidemiology, etiology, pathogenesis, clinical manifestations, management, and differential diagnosis. Some key points:
- Dengue is a mosquito-borne viral disease spread by Aedes mosquitoes and endemic in most parts of the world except Europe. It has four serotypes.
- The virus causes capillary damage and fluid leakage, which can lead to hypovolemia, shock, organ dysfunction, and hemorrhage in severe cases. Secondary infection with a new serotype increases risk.
- Clinical phases include fever, critical, and recovery. Warning signs like abdominal pain, vomiting indicate risk of severe disease. Management involves fluid management, monitoring for shock
This document provides information on dengue fever, a mosquito-borne viral infection. It discusses the clinical presentation and pathophysiology of dengue fever and the more severe forms of dengue hemorrhagic fever and dengue shock syndrome. Key points include that dengue fever presents as an acute febrile illness and is caused by one of four related viruses. In rare cases it can progress to dengue hemorrhagic fever or dengue shock syndrome, characterized by bleeding and shock. Treatment involves supportive care and fluid replacement for dehydration.
This document provides information on Dengue fever, including:
1) It is caused by Dengue virus which has 4 serotypes transmitted by Aedes mosquitoes.
2) It progresses through 3 phases: febrile, critical, and recovery. The critical phase can involve warning signs like severe bleeding.
3) Diagnosis is based on symptoms and lab tests showing thrombocytopenia. There is no vaccine or specific treatment, only supportive care.
4) Management involves monitoring for warning signs and providing intravenous fluids and blood products if needed to prevent shock. The goal is early detection and treatment of complications.
This document discusses fluid treatment choices for dengue infection. It begins with an overview of dengue classification and pathophysiology. It then reviews several randomized controlled trials comparing crystalloid and colloid fluid treatments for dengue shock syndrome. The trials found that most patients can be successfully treated with crystalloids alone. For more severe cases, colloids may provide initial volume expansion but have a higher risk of allergic reactions. The document concludes that crystalloids are usually sufficient but colloids may be considered based on individual circumstances.
This document discusses dengue fever, caused by the Aedes mosquito. It notes that dengue illness predominantly affects pediatric populations and can have a high mortality rate. Clinical presentation can vary widely, from fever to bleeding to shock. The disease progresses through febrile, leaky, and congestive phases. Diagnosis involves clinical observation, hematological tests, and virological methods. Management is supportive through monitoring and intervening early if warning signs appear. Prognosis is favorable with early recognition and treatment of plasma leakage and thrombocytopenia. Prevention focuses on eliminating mosquito breeding sites and preventing bites.
This review article discusses autoimmunity in dengue pathogenesis. It suggests that in addition to direct viral effects, immunopathogenesis, including aberrant immune activation and autoantibodies, plays a role in the development of severe dengue disease. Autoantibodies against endothelial cells, platelets, and coagulation molecules induced by dengue virus infection may lead to abnormal activation or dysfunction of these cells and molecules. Molecular mimicry, where dengue virus proteins mimic host proteins, could explain the cross-reactivity of autoantibodies induced during dengue virus infection. Understanding immunopathogenic mechanisms is important for developing a safe and effective dengue vaccine.
MedicYatra provides the safe & best DENGUE Fever treatment and procedure at its affiliate & trusted hospitals & clinics in various metro cities of India, like Mumbai, Delhi, Bangalore, Chennai, Pune etc.Our Associate Board certified doctors are extensively trained and vastly experienced and have performed hundreds of such cases at our state of the art JCI accredited hospitals & Clinics. Our aim is to provide you the best of the services at the most affordable costs. Don't forget to say hi at info@medicyatra.com
Dengue fever is a prevalent mosquito-borne illness caused by dengue virus and transmitted by Aedes aegypti mosquitoes. It affects over 100 countries and causes 50-100 million infections annually. The disease presentation varies from a nonspecific viral syndrome to severe dengue hemorrhagic fever/dengue shock syndrome. There is no vaccine currently available and treatment involves supportive care, with careful fluid management needed for severe cases to prevent shock. Prevention relies on personal protection from mosquito bites and reducing mosquito breeding sites.
This document discusses dengue in children, including its epidemiology, etiology, pathogenesis, clinical manifestations, management, and differential diagnosis. Some key points:
- Dengue is a mosquito-borne viral disease spread by Aedes mosquitoes and endemic in most parts of the world except Europe. It has four serotypes.
- The virus causes capillary damage and fluid leakage, which can lead to hypovolemia, shock, organ dysfunction, and hemorrhage in severe cases. Secondary infection with a new serotype increases risk.
- Clinical phases include fever, critical, and recovery. Warning signs like abdominal pain, vomiting indicate risk of severe disease. Management involves fluid management, monitoring for shock
This document provides information on dengue fever, a mosquito-borne viral infection. It discusses the clinical presentation and pathophysiology of dengue fever and the more severe forms of dengue hemorrhagic fever and dengue shock syndrome. Key points include that dengue fever presents as an acute febrile illness and is caused by one of four related viruses. In rare cases it can progress to dengue hemorrhagic fever or dengue shock syndrome, characterized by bleeding and shock. Treatment involves supportive care and fluid replacement for dehydration.
Here are 5 key steps individuals can take to prevent dengue:
1. Remove stagnant water from containers, flower vases, etc.
2. Use mosquito nets and repellents.
3. Wear full-sleeved clothes to cover exposed skin.
4. Seek medical help if experiencing fever and symptoms like headache, pain behind eyes, muscle and joint pain.
5. Support community efforts to raise awareness and eliminate mosquito breeding sites.
The document discusses properties, modes of action, indications, and administration of intravenous immunoglobulin (IVIg). It provides details on the plasma fractionation process used to produce IVIg and notes that IVIg contains 98% IgG and traces of other immunoglobulins. The document also examines IVIg's mechanisms of action, FDA-approved uses, evidence for off-label uses, and potential adverse effects.
The document provides information on Dengue Fever, including that it is caused by a mosquito-borne flavivirus transmitted by Aedes aegypti and Aedes albopictus mosquitoes. It has four serotypes that provide varying levels of immunity. Symptoms include fever, headache, rash and bleeding. Diagnosis involves antibody and viral testing. Severe dengue is classified as dengue hemorrhagic fever or dengue shock syndrome, characterized by bleeding, low platelets and plasma leakage. Monitoring of patients involves serial complete blood counts and hematocrit levels to detect signs of plasma leakage. Proper fluid management and monitoring for bleeding and organ dysfunction is important throughout the illness.
Dengue fever is an acute, self-limited, febrile disease caused by dengue virus and transmitted by Aedes aegypti mosquitoes. It occurs in two forms: dengue fever and dengue hemorrhagic fever. Dengue fever involves fever, headache, rash and joint pain while dengue hemorrhagic fever involves high fever, bleeding, organ involvement and signs of circulatory failure. Diagnosis involves clinical presentation and serological tests to detect antibodies or viral components. Treatment focuses on fluid replacement and supportive care, with monitoring to prevent shock in dengue hemorrhagic fever cases. Prevention emphasizes mosquito control and personal protection measures.
IVIG is a solution of purified IgG antibodies derived from pooled human plasma. It is administered intravenously or subcutaneously to provide passive immunity to patients with primary immunodeficiencies or conditions affecting antibody production. IVIG treatment can be administered safely at home with a visiting nurse and is used to treat a wide range of immune disorders by replacing and maintaining adequate antibody levels against infection.
The document provides guidelines on dengue infection, discussing the clinical syndromes of dengue fever and dengue hemorrhagic fever, their diagnosis and classification, management approaches including fluid resuscitation, and treatment of complications. It describes dengue virus and the disease it causes, including its pathophysiology, clinical course, and atypical manifestations. Risk factors, vectors, and the immune response to primary and secondary infections are also covered.
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
Dengue fever, also known as breakbone fever, is caused by the dengue virus and transmitted by Aedes mosquitoes. It is endemic in over 110 countries, infecting 50-100 million people annually. Symptoms include high fever, headache, muscle and joint pains, and a rash. In a small percentage of cases, it can develop into severe dengue hemorrhagic fever or dengue shock syndrome, which can be life-threatening. There is no vaccine, so prevention depends on controlling mosquito populations and avoiding bites. Nurses play an important role in monitoring patients, providing rehydration and blood transfusions if needed, and educating on prevention.
This document provides information about dengue fever, including its definition, transmission, symptoms, treatment, and prevention. It states that dengue is a mosquito-borne virus found in tropical and subtropical regions worldwide. The virus is transmitted by the bites of infected Aedes aegypti mosquitoes and has an incubation period of 4-10 days in humans. Common symptoms include high fever, headache, muscle pains, and rash. Treatment focuses on medical care and fluid maintenance to prevent complications. Prevention involves eliminating mosquito breeding sites and following government advisories.
1) Dengue fever is caused by mosquitoes of the genus Aedes, mainly A. aegypti, and is prevalent during rainy seasons when mosquito populations increase. Improper waste disposal also contributes to mosquito propagation.
2) Dengue virus consists of 4 serotypes that cause disease in humans. Major epidemics have occurred across Asia and there have been recent outbreaks in Pakistan.
3) Clinical presentation ranges from mild dengue fever to severe dengue hemorrhagic fever/dengue shock syndrome. Outpatient management is usually sufficient but hospitalization may be needed for dehydration, bleeding, or low platelet count. Prevention relies on environmental controls and public education.
Dengue fever is caused by the dengue virus, which is transmitted by the Aedes aegypti mosquito. It has four distinct serotypes. The virus replicates in the mosquito and humans, who serve as the primary reservoir of infection. Symptoms range from a mild fever to the potentially lethal dengue hemorrhagic fever. There is no vaccine, so prevention depends on controlling the mosquito population and avoiding bites.
Dengue fever is a mosquito-borne viral illness characterized by fever, rash, and joint pains. It is caused by any of four dengue virus serotypes. The disease ranges from a mild febrile illness to severe dengue, which can be fatal. It is increasingly prevalent worldwide in tropical and subtropical regions. Early recognition and fluid therapy are important to prevent complications and reduce mortality. While there is no vaccine, prevention focuses on controlling the Aedes mosquito population and eliminating breeding sites.
This document provides guidelines for the diagnosis, treatment, prevention and control of dengue. It is a joint publication of the World Health Organization and the Special Programme for Research and Training in Tropical Diseases. The guidelines cover epidemiology and transmission of dengue virus, clinical management and delivery of clinical services, vector management and delivery of vector control services, laboratory diagnosis and diagnostic tests, and surveillance, emergency preparedness and response. New avenues of research on dengue vaccines and antiviral drugs are also discussed. The guidelines are intended to assist health workers and researchers in dengue prevention and control efforts.
This document provides an overview and summary of the 2009 WHO guidelines for the diagnosis, treatment, prevention and control of dengue. It outlines the epidemiology and burden of dengue disease globally and the modes of transmission. It describes recommendations for the clinical management of cases and delivery of clinical services. It discusses methods of vector control and delivery of vector control interventions. It covers current diagnostic methods and quality assurance in laboratories. It also addresses dengue surveillance, emergency preparedness and response. Finally, it presents new avenues of research including dengue vaccines and antiviral drugs. The guidelines are intended to provide up-to-date practical information for health practitioners, laboratories, vector control experts and public health officials worldwide.
This document provides an overview and summary of the 2009 WHO guidelines for the diagnosis, treatment, prevention and control of dengue. It outlines the epidemiology and burden of dengue disease globally and the modes of transmission. It describes recommendations for the clinical management of cases and delivery of clinical services. It discusses methods of vector control and delivery of vector control interventions. It covers current diagnostic methods and quality assurance in laboratories. It also addresses dengue surveillance, emergency preparedness and response. Finally, it presents new avenues of research including dengue vaccines and antiviral drugs. The guidelines are intended to provide up-to-date practical information for health practitioners, laboratories, vector control experts and public health officials worldwide.
This document provides guidelines for infection control in dental health care settings. It consolidates previous recommendations and adds new ones regarding educating and protecting dental health care personnel, preventing transmission of bloodborne pathogens, hand hygiene, personal protective equipment, contact dermatitis and latex sensitivity, sterilization and disinfection, environmental infection control, dental unit waterlines, and special considerations such as dental handpieces, radiology, parenteral medications, and oral surgery. The recommendations were developed by the CDC in collaboration with other experts and are based on available scientific evidence and expert opinion.
This document provides an introduction and overview of a manual for developing medical record systems. It aims to help medical record workers develop and manage effective and efficient medical record departments. Key points covered include the objectives of medical record management, national and international support for the field, common terminology and name changes over time, and an overview of what will be covered in the manual such as the medical record, medical record department functions, basic procedures, and quality and legal issues. The introduction emphasizes the importance of having complete and accurate medical records available for patient care.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations met in October 2004 to consider matters concerning quality assurance of pharmaceuticals. Key topics discussed included proposed monographs for inclusion in The International Pharmacopoeia, quality specifications for antiretroviral and antituberculosis drugs, good manufacturing practices, inspection procedures, distribution standards, and guidelines for fixed-dose combination medicines. The Committee adopted several new standards and guidelines and made recommendations on advancing additional work in priority areas.
Introducing zinc in a diarrheal disease control programPaul Mark Pilar
This document provides guidance on conducting formative research to introduce zinc as a treatment for childhood diarrhea in developing countries. The research involves 8 steps: 1) understanding local concepts and practices related to diarrhea; 2) developing culturally appropriate messages about zinc; 3) testing message effectiveness; 4) gathering feedback on zinc tablets; 5) designing labels and logos; 6) developing counseling materials; 7) conducting a behavioral trial; and 8) planning for future zinc promotion. The goal is to introduce zinc in a way that enhances, rather than undermines, existing efforts to promote oral rehydration solutions for diarrhea treatment and prevention.
This document provides guidance on standard operating procedures (SOPs) and master formulae for vaccine manufacturers. It summarizes WHO requirements for documentation and written procedures. Sample SOP formats, examples of SOP content, and master formula templates are provided. The document aims to help manufacturers develop comprehensive documentation systems required for compliance with good manufacturing practices (GMP).
This document provides comprehensive guidelines for the prevention and control of dengue and dengue haemorrhagic fever (DHF) revised and expanded by the World Health Organization (WHO) in 2011. It covers the disease burden globally and in the WHO South-East Asia region, epidemiology of dengue virus and vectors, clinical diagnosis and management, laboratory diagnosis, surveillance, vector biology and management, integrated vector management, communication strategies, and multi-sectoral approaches. The guidelines are intended to provide guidance to national and local programmes in strengthening response to dengue.
The document is a quick reference guide for the prevention and treatment of pressure ulcers published by the National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, and Pan Pacific Pressure Injury Alliance. It provides concise summaries and recommendations based on an evidence review. The guide defines key terms, outlines risk assessment and prevention strategies like nutrition, repositioning and support surfaces. It also covers treatment methods such as wound dressings, debridement and biophysical agents. Special populations like bariatric and critically ill individuals are addressed as well.
Here are 5 key steps individuals can take to prevent dengue:
1. Remove stagnant water from containers, flower vases, etc.
2. Use mosquito nets and repellents.
3. Wear full-sleeved clothes to cover exposed skin.
4. Seek medical help if experiencing fever and symptoms like headache, pain behind eyes, muscle and joint pain.
5. Support community efforts to raise awareness and eliminate mosquito breeding sites.
The document discusses properties, modes of action, indications, and administration of intravenous immunoglobulin (IVIg). It provides details on the plasma fractionation process used to produce IVIg and notes that IVIg contains 98% IgG and traces of other immunoglobulins. The document also examines IVIg's mechanisms of action, FDA-approved uses, evidence for off-label uses, and potential adverse effects.
The document provides information on Dengue Fever, including that it is caused by a mosquito-borne flavivirus transmitted by Aedes aegypti and Aedes albopictus mosquitoes. It has four serotypes that provide varying levels of immunity. Symptoms include fever, headache, rash and bleeding. Diagnosis involves antibody and viral testing. Severe dengue is classified as dengue hemorrhagic fever or dengue shock syndrome, characterized by bleeding, low platelets and plasma leakage. Monitoring of patients involves serial complete blood counts and hematocrit levels to detect signs of plasma leakage. Proper fluid management and monitoring for bleeding and organ dysfunction is important throughout the illness.
Dengue fever is an acute, self-limited, febrile disease caused by dengue virus and transmitted by Aedes aegypti mosquitoes. It occurs in two forms: dengue fever and dengue hemorrhagic fever. Dengue fever involves fever, headache, rash and joint pain while dengue hemorrhagic fever involves high fever, bleeding, organ involvement and signs of circulatory failure. Diagnosis involves clinical presentation and serological tests to detect antibodies or viral components. Treatment focuses on fluid replacement and supportive care, with monitoring to prevent shock in dengue hemorrhagic fever cases. Prevention emphasizes mosquito control and personal protection measures.
IVIG is a solution of purified IgG antibodies derived from pooled human plasma. It is administered intravenously or subcutaneously to provide passive immunity to patients with primary immunodeficiencies or conditions affecting antibody production. IVIG treatment can be administered safely at home with a visiting nurse and is used to treat a wide range of immune disorders by replacing and maintaining adequate antibody levels against infection.
The document provides guidelines on dengue infection, discussing the clinical syndromes of dengue fever and dengue hemorrhagic fever, their diagnosis and classification, management approaches including fluid resuscitation, and treatment of complications. It describes dengue virus and the disease it causes, including its pathophysiology, clinical course, and atypical manifestations. Risk factors, vectors, and the immune response to primary and secondary infections are also covered.
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
Dengue fever, also known as breakbone fever, is caused by the dengue virus and transmitted by Aedes mosquitoes. It is endemic in over 110 countries, infecting 50-100 million people annually. Symptoms include high fever, headache, muscle and joint pains, and a rash. In a small percentage of cases, it can develop into severe dengue hemorrhagic fever or dengue shock syndrome, which can be life-threatening. There is no vaccine, so prevention depends on controlling mosquito populations and avoiding bites. Nurses play an important role in monitoring patients, providing rehydration and blood transfusions if needed, and educating on prevention.
This document provides information about dengue fever, including its definition, transmission, symptoms, treatment, and prevention. It states that dengue is a mosquito-borne virus found in tropical and subtropical regions worldwide. The virus is transmitted by the bites of infected Aedes aegypti mosquitoes and has an incubation period of 4-10 days in humans. Common symptoms include high fever, headache, muscle pains, and rash. Treatment focuses on medical care and fluid maintenance to prevent complications. Prevention involves eliminating mosquito breeding sites and following government advisories.
1) Dengue fever is caused by mosquitoes of the genus Aedes, mainly A. aegypti, and is prevalent during rainy seasons when mosquito populations increase. Improper waste disposal also contributes to mosquito propagation.
2) Dengue virus consists of 4 serotypes that cause disease in humans. Major epidemics have occurred across Asia and there have been recent outbreaks in Pakistan.
3) Clinical presentation ranges from mild dengue fever to severe dengue hemorrhagic fever/dengue shock syndrome. Outpatient management is usually sufficient but hospitalization may be needed for dehydration, bleeding, or low platelet count. Prevention relies on environmental controls and public education.
Dengue fever is caused by the dengue virus, which is transmitted by the Aedes aegypti mosquito. It has four distinct serotypes. The virus replicates in the mosquito and humans, who serve as the primary reservoir of infection. Symptoms range from a mild fever to the potentially lethal dengue hemorrhagic fever. There is no vaccine, so prevention depends on controlling the mosquito population and avoiding bites.
Dengue fever is a mosquito-borne viral illness characterized by fever, rash, and joint pains. It is caused by any of four dengue virus serotypes. The disease ranges from a mild febrile illness to severe dengue, which can be fatal. It is increasingly prevalent worldwide in tropical and subtropical regions. Early recognition and fluid therapy are important to prevent complications and reduce mortality. While there is no vaccine, prevention focuses on controlling the Aedes mosquito population and eliminating breeding sites.
This document provides guidelines for the diagnosis, treatment, prevention and control of dengue. It is a joint publication of the World Health Organization and the Special Programme for Research and Training in Tropical Diseases. The guidelines cover epidemiology and transmission of dengue virus, clinical management and delivery of clinical services, vector management and delivery of vector control services, laboratory diagnosis and diagnostic tests, and surveillance, emergency preparedness and response. New avenues of research on dengue vaccines and antiviral drugs are also discussed. The guidelines are intended to assist health workers and researchers in dengue prevention and control efforts.
This document provides an overview and summary of the 2009 WHO guidelines for the diagnosis, treatment, prevention and control of dengue. It outlines the epidemiology and burden of dengue disease globally and the modes of transmission. It describes recommendations for the clinical management of cases and delivery of clinical services. It discusses methods of vector control and delivery of vector control interventions. It covers current diagnostic methods and quality assurance in laboratories. It also addresses dengue surveillance, emergency preparedness and response. Finally, it presents new avenues of research including dengue vaccines and antiviral drugs. The guidelines are intended to provide up-to-date practical information for health practitioners, laboratories, vector control experts and public health officials worldwide.
This document provides an overview and summary of the 2009 WHO guidelines for the diagnosis, treatment, prevention and control of dengue. It outlines the epidemiology and burden of dengue disease globally and the modes of transmission. It describes recommendations for the clinical management of cases and delivery of clinical services. It discusses methods of vector control and delivery of vector control interventions. It covers current diagnostic methods and quality assurance in laboratories. It also addresses dengue surveillance, emergency preparedness and response. Finally, it presents new avenues of research including dengue vaccines and antiviral drugs. The guidelines are intended to provide up-to-date practical information for health practitioners, laboratories, vector control experts and public health officials worldwide.
This document provides guidelines for infection control in dental health care settings. It consolidates previous recommendations and adds new ones regarding educating and protecting dental health care personnel, preventing transmission of bloodborne pathogens, hand hygiene, personal protective equipment, contact dermatitis and latex sensitivity, sterilization and disinfection, environmental infection control, dental unit waterlines, and special considerations such as dental handpieces, radiology, parenteral medications, and oral surgery. The recommendations were developed by the CDC in collaboration with other experts and are based on available scientific evidence and expert opinion.
This document provides an introduction and overview of a manual for developing medical record systems. It aims to help medical record workers develop and manage effective and efficient medical record departments. Key points covered include the objectives of medical record management, national and international support for the field, common terminology and name changes over time, and an overview of what will be covered in the manual such as the medical record, medical record department functions, basic procedures, and quality and legal issues. The introduction emphasizes the importance of having complete and accurate medical records available for patient care.
The WHO Expert Committee on Specifications for Pharmaceutical Preparations met in October 2004 to consider matters concerning quality assurance of pharmaceuticals. Key topics discussed included proposed monographs for inclusion in The International Pharmacopoeia, quality specifications for antiretroviral and antituberculosis drugs, good manufacturing practices, inspection procedures, distribution standards, and guidelines for fixed-dose combination medicines. The Committee adopted several new standards and guidelines and made recommendations on advancing additional work in priority areas.
Introducing zinc in a diarrheal disease control programPaul Mark Pilar
This document provides guidance on conducting formative research to introduce zinc as a treatment for childhood diarrhea in developing countries. The research involves 8 steps: 1) understanding local concepts and practices related to diarrhea; 2) developing culturally appropriate messages about zinc; 3) testing message effectiveness; 4) gathering feedback on zinc tablets; 5) designing labels and logos; 6) developing counseling materials; 7) conducting a behavioral trial; and 8) planning for future zinc promotion. The goal is to introduce zinc in a way that enhances, rather than undermines, existing efforts to promote oral rehydration solutions for diarrhea treatment and prevention.
This document provides guidance on standard operating procedures (SOPs) and master formulae for vaccine manufacturers. It summarizes WHO requirements for documentation and written procedures. Sample SOP formats, examples of SOP content, and master formula templates are provided. The document aims to help manufacturers develop comprehensive documentation systems required for compliance with good manufacturing practices (GMP).
This document provides comprehensive guidelines for the prevention and control of dengue and dengue haemorrhagic fever (DHF) revised and expanded by the World Health Organization (WHO) in 2011. It covers the disease burden globally and in the WHO South-East Asia region, epidemiology of dengue virus and vectors, clinical diagnosis and management, laboratory diagnosis, surveillance, vector biology and management, integrated vector management, communication strategies, and multi-sectoral approaches. The guidelines are intended to provide guidance to national and local programmes in strengthening response to dengue.
The document is a quick reference guide for the prevention and treatment of pressure ulcers published by the National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, and Pan Pacific Pressure Injury Alliance. It provides concise summaries and recommendations based on an evidence review. The guide defines key terms, outlines risk assessment and prevention strategies like nutrition, repositioning and support surfaces. It also covers treatment methods such as wound dressings, debridement and biophysical agents. Special populations like bariatric and critically ill individuals are addressed as well.
Monitoring and evaluation toolkit - Conférence de la 2e édition du Cours international « Atelier Paludisme » - TUSEO Luciano - World Health Organization / Roll Back Malaria - maloms@iris.mg
The document discusses the development of a New Zealand Universal List of Medicines (NZULM) and New Zealand Medicines Formulary (NZMF) to standardize medicines terminology and information across the country's health system. The NZULM will contain basic information about medicines and medical devices while the NZMF will include the NZULM information plus additional clinical guidance. Both are intended to improve patient safety, healthcare efficiency and outcomes by providing a single authoritative source for medicines data.
This document provides a draft summary of guidelines for the psychosocial management of drug misuse. It discusses key priorities for implementation, including providing information to drug users about treatment options, offering brief interventions, promoting self-help groups, introducing contingency management programs, considering family-based interventions, and using incentives to encourage participation in interventions to improve physical health. The draft guidelines contained in the document cover general principles of care, identification and recognition of drug misuse, brief and low-intensity interventions, structured psychosocial interventions, and residential, prison and inpatient care.
Who therapeutics and covid 19 living guideline, march 2022 PDFDr Notes
Who therapeutics and covid 19 living guideline, march 2022
Download link
https://dr-notes.com/who-therapeutics-and-covid-19-living-guideline-march-2022-ijp
This document provides a summary of recommendations for preventing and treating pressure ulcers from an international guideline developed by the National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, and Pan Pacific Pressure Injury Alliance. The guideline aims to assist healthcare professionals in providing evidence-based care for individuals at risk of or experiencing pressure ulcers. It was developed using an explicit scientific methodology and consensus process to evaluate available research studies and expert opinions. Printed copies of the full clinical practice guideline are available in English through the websites of the collaborating organizations.
The document provides guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. It was developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. The guidelines were updated on December 1, 2009 with key changes including earlier initiation of antiretroviral therapy based on CD4 count, addition of raltegravir as a preferred regimen, and changes to treatment recommendations for treatment-experienced patients.
The document provides a quick reference guide that summarizes recommendations from NICE on the management of rheumatoid arthritis in adults. It was developed by the National Collaborating Centre for Chronic Conditions and reviewed by healthcare professionals and patients. The guide outlines priorities for referral, use of disease-modifying drugs and biologicals, monitoring disease activity, and the roles of the multidisciplinary team and surgery in management. It is intended to help rheumatologists, GPs, and other staff caring for people with rheumatoid arthritis.
This document provides guidelines for standardized calibration procedures for brachytherapy sources at secondary standards dosimetry laboratories (SSDLs) and hospitals. It discusses the calibration of 137Cs reference sources using cavity ionization chambers at SSDLs and hospitals. Procedures are described for calibrating brachytherapy sources such as high-dose rate (HDR) sources, low-dose rate (LDR) sources, and 125I seeds using well-type ionization chambers. Quality control procedures are also outlined to ensure safety and consistency in brachytherapy source calibrations.
WHO Guideline on Quality Risk Management PostgradoMLCC
This document outlines a proposed guideline on quality risk management from the World Health Organization. It discusses applying risk management principles to both medicines regulatory authorities and pharmaceutical manufacturers. The goal is to help focus resources on risks to patients, encourage science-based decision making, and improve communication between organizations. The draft guideline is being circulated for comment before finalization.
OBJECTIVE:
To provide systematic, standardized and high quality wound care in healthcare facilities hence improving patient’s functional outcome and reducing healthcare cost.
Specific Objective:
- To estimate the total burden of wound managed by wound care team in the selected hospitals.
- To determine the characteristic of wound ‐ types of wound, dressing procedures and materials used.
- To assess the outcome of wound care.
- To provide a standardized tool for hospitals to identify targets for quality improvement.
Similar to Dengue guidelines for diagnosis treatment prevention and control (20)
Informal consultation on clinical use of oxygenPaul Mark Pilar
This document summarizes a meeting that discussed improving clinical oxygen therapy in small hospitals in developing countries. Key topics included:
- The epidemiology of hypoxemia in various patient populations and settings. It is a major problem in children, neonates, surgery, and obstetrics.
- Availability of oxygen is often limited in district hospitals in developing countries. Surveys found oxygen unavailable or not delivered effectively.
- Experience introducing oxygen concentrators in Malawi as part of a child lung health program, which helped make oxygen available in more hospitals.
- Available oxygen sources like concentrators, with a focus on appropriate models for developing country settings.
- Indications for oxygen therapy and methods of monitoring and delivery.
Infant and young child feeding a tool for assessing national practices polici...Paul Mark Pilar
This document provides a tool for assessing national practices, policies, and programs related to infant and young child feeding. It contains three parts:
1. An assessment of key infant feeding practices based on WHO indicators.
2. An evaluation of national policies and achievement of targets from the Innocenti Declaration and Global Strategy.
3. An analysis of components of a comprehensive national infant feeding program.
The tool is designed to help countries identify strengths and weaknesses in order to improve protection, promotion, and support of optimal infant feeding. It can assist in developing plans and tracking progress toward global goals.
This document discusses improving child health through community-based approaches. It notes that while medical treatment has reduced childhood deaths, many children still die without receiving care. A community-based approach involves local people, adapts to community needs, and builds on existing resources by enhancing community structures and expertise. The key is introducing crucial child care practices widely, like exclusive breastfeeding for six months, appropriate complementary feeding, ensuring good nutrition, treating childhood illnesses at home when possible and seeking care when needed.
Improving child health imci the integrated approachPaul Mark Pilar
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Implementation manual who surgical safety checklist 2009Paul Mark Pilar
The document is an implementation manual for the WHO Surgical Safety Checklist from 2009. It provides guidance on how to use the checklist to improve safety in the operating room. The checklist divides surgery into three phases - before induction of anesthesia, before skin incision, and before the patient leaves the operating room. It describes the safety steps to be completed in each phase, including confirming the patient's identity and consent, checking for allergies, and making sure counts are correct before the patient leaves the OR. The goal is for teams to consistently follow critical safety steps to minimize risks for surgical patients.
Indicators for assessing infacnt and young child feeding practicesPaul Mark Pilar
This document provides guidance on measuring indicators for assessing infant and young child feeding practices. It includes an example questionnaire with modules on household rosters, initiation of breastfeeding, and infant and young child feeding. It also provides instructions for interviewers on administering the questionnaire. Additionally, the document offers suggestions for adapting the questionnaire based on survey context. Finally, it details the calculations needed to determine indicator values from the collected data, including early initiation of breastfeeding, exclusive breastfeeding under 6 months, and minimum acceptable diet. The goal is to improve the standardized and accurate measurement of these important infant feeding indicators.
This document summarizes an update published in 2007 on HIV transmission through breastfeeding. It reviews scientific evidence from 2001 to 2007 on the risk of HIV transmission through breastfeeding, the impact of different infant feeding options on child health outcomes, and strategies to reduce transmission through breastfeeding in developing countries. The update aims to inform public health recommendations around infant feeding by HIV-infected mothers.
Guidelines prevention and_management_wound_infectionPaul Mark Pilar
This document provides guidance from the WHO on preventing and managing wound infections. It outlines three key principles: do not close infected wounds, do not close contaminated wounds that are over six hours old, and use antibiotic prophylaxis and surgical debridement to prevent infections. It then describes three protocols: 1) wound toilet and surgical debridement to clean wounds, 2) management of tetanus-prone wounds with vaccination and immunoglobulin, and 3) antibiotic prophylaxis and treatment for wounds at high risk of infection.
Global priorities for patient safety researchPaul Mark Pilar
This document outlines global priorities for patient safety research as identified by a WHO expert group. The group found common priorities across developing, transitional, and developed countries including inadequate training and skills, lack of communication, and healthcare-associated infections. They developed a table of the top six priorities for each setting and identified over 50 priority research topics and questions. The document calls for more applied, evaluative research to develop effective and affordable solutions to improve patient safety worldwide.
1) Home visits for newborns in the first week of life can prevent 30-60% of newborn deaths in high mortality settings. WHO and UNICEF now recommend at least two home visits for all home births - one within 24 hours of birth and another on day 3.
2) During home visits, health workers should promote practices like exclusive breastfeeding, keeping the baby warm, and hygienic cord and skin care. They should also identify danger signs and counsel families on care seeking. Additional care is needed for low birthweight and sick newborns.
3) In many developing countries, community health workers can conduct home visits when skilled attendants are not available. Home visits help improve new
Foundation module the midwife in the communityPaul Mark Pilar
This document provides an introduction to a set of midwifery education modules developed by the World Health Organization (WHO) to help upgrade midwifery skills and strengthen maternal and newborn health services. The modules aim to help midwives and others develop skills to respond appropriately to major causes of maternal mortality such as hemorrhage, abortion complications, obstructed labor, puerperal sepsis, and eclampsia. The modules cover topics like managing complications in pregnancy and childbirth, the midwife's role in the community, and include skills for both prevention and management of complications as well as general midwifery skills. They are intended to be used for in-service training of midwives but can also
Family and community practices that promote child survival growth and develop...Paul Mark Pilar
The document reviews evidence on 12 key family and community practices that promote child survival, growth, and development. It finds that interventions to improve each of the practices have the potential to substantially reduce child mortality and morbidity and improve development. However, the potential impact varies between practices depending on current prevalence, the strength of evidence linking the practice to outcomes, and the feasibility and effectiveness of interventions to increase the practice. It identifies gaps in knowledge about some practices, such as how to best improve care-seeking. The review confirms the importance of the practices but finds that more evidence is still needed to guide the development and evaluation of large-scale programs in some areas.
Evidence for the ten steps to succesful breastfeedingPaul Mark Pilar
This document reviews evidence for the Ten Steps to Successful Breastfeeding, which are the foundation of the WHO/UNICEF Baby Friendly Hospital Initiative. The review finds that implementing each individual Step has some positive effect on breastfeeding outcomes, but implementing all Ten Steps together can have the greatest impact. Conversely, omitting one or more Steps may limit the overall effectiveness of those that are in place. The evidence shows improved breastfeeding rates across different settings and cultures from implementing the Ten Steps within maternity facilities. While many other factors also influence breastfeeding, improving healthcare practices through the Ten Steps is seen as fundamental to realizing gains from other breastfeeding promotion activities. The review methodology prioritizes experimental and quasi-experimental studies, with
Evidence on the long term effects of brestfeedingPaul Mark Pilar
This document presents a summary of 5 systematic reviews on the long-term effects of breastfeeding. The reviews examined the relationship between breastfeeding and blood pressure, cholesterol levels, risk of overweight/obesity, risk of type-2 diabetes, and school achievement/intelligence. The reviews found that breastfeeding was associated with lower blood pressure and cholesterol levels in adulthood, lower risk of overweight/obesity, and lower risk of type-2 diabetes. Breastfeeding was also associated with higher school achievement and intelligence levels, although there was more heterogeneity in those findings. Publication bias and residual confounding did not fully explain the observed effects, suggesting that breastfeeding provides meaningful long-term health benefits.
Evidence for the ten steps to succesful breastfeedingPaul Mark Pilar
This document provides evidence for the Ten Steps to Successful Breastfeeding as outlined by the World Health Organization. It summarizes research showing that implementing policies to support breastfeeding, training health care staff, preparing mothers during pregnancy, ensuring early skin-to-skin contact and breastfeeding, providing breastfeeding guidance, restricting formula and pacifier use, practicing rooming-in, and feeding on demand all have significant benefits for increasing breastfeeding rates and improving health outcomes for both mothers and babies. The document concludes that fully implementing these Ten Steps is an effective global strategy for promoting and supporting breastfeeding.
This document provides guidance on simple treatment methods for emergency drinking water at the point-of-use. It describes straining water through a clean cloth to remove debris, aeration to increase oxygen and remove contaminants, and storage to allow settling and die-off of bacteria over time. It also outlines basic filtration methods like sand filters and charcoal or ceramic filters, noting that filtered water still requires disinfection. Proper treatment can provide a safe short-term water supply until a long-term solution is established.
Developmental difficulties in early childhoodPaul Mark Pilar
This document summarizes research on developmental difficulties in early childhood, with a focus on low- and middle-income countries. It covers topics such as conceptualizing child development and risk factors, epidemiology of developmental difficulties, prevention, early detection, assessment, classification systems, and early intervention. The overall aim is to review evidence on supporting healthy development and addressing developmental difficulties in young children living in resource-poor settings.
Community based strategies for breastfeeding promotion and support in develop...Paul Mark Pilar
This document discusses community-based strategies for promoting and supporting breastfeeding in developing countries. It summarizes evidence that community interventions can effectively improve breastfeeding practices and associated health outcomes for infants and mothers. Key factors for successful community interventions include partnerships, formative research, monitoring and evaluation, training, management, and integrating breastfeeding promotion into primary health services. Case studies from Madagascar, Honduras, and India demonstrate positive impacts of community-based approaches.
This document provides guidance on communicable disease control in emergency situations. It covers topics such as rapid assessment, prevention, surveillance, outbreak control, and the prevention and control of specific diseases. The document was edited by M.A. Connolly and published by the World Health Organization in 2005. It aims to provide public health workers with the information needed to effectively respond to communicable disease outbreaks during humanitarian emergencies.
Here are the key steps to assess for an airway or breathing problem:
1. Look at the child's chest - is it rising and falling with each breath? Listen at the child's mouth and nose for sounds of breathing.
2. Check for central cyanosis - a bluish color of the tongue and lips caused by lack of oxygen in the blood. Cyanosis is an emergency sign.
3. Observe the child's breathing pattern - is it fast (over 60 breaths per minute for infants under 2 months, over 50 breaths per minute for children 2 months to 1 year, over 40 breaths per minute for children 1 to 5 years)? Is there chest indrawing? These are signs of respiratory distress and an
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfrightmanforbloodline
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Lecture 6 -- Memory 2015.pptlearning occurs when a stimulus (unconditioned st...AyushGadhvi1
learning occurs when a stimulus (unconditioned stimulus) eliciting a response (unconditioned response) • is paired with another stimulus (conditioned stimulus)
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Dengue guidelines for diagnosis treatment prevention and control
1. DENGUE GUIDELINES FOR DIAGNOSIS, TREATMENT, PREVENTION AND CONTROL
DENGUE
GUIDELINES FOR DIAGNOSIS,
TREATMENT, PREVENTION AND CONTROL
New edition
2009
New edition
Neglected Tropical Diseases (NTD) TDR/World Health Organization
HIV/AIDS, Tuberculosis and Malaria (HTM) 20, Avenue Appia
World Health Organization 1211 Geneva 27
Avenue Appia 20, 1211 Geneva 27, Switzerland Switzerland
Fax: +41 22 791 48 69 Fax: +41 22 791 48 54
www.who.int/neglected_diseases/en www.who.int/tdr
neglected.diseases@who.int tdr@who.int
2.
3. DENGUE
GUIDELINES FOR DIAGNOSIS,
TREATMENT, PREVENTION AND CONTROL
New edition
2009
A joint publication of the World Health Organization (WHO) and the Special Programme for Research
and Training in Tropical Diseases (TDR)
7. Introduction, Methodology, Acknowledgements, Abbreviations, Preface
PREFACE
Since the second edition of Dengue haemorrhagic fever: diagnosis, treatment, prevention
and control was published by the World Health Organization (WHO) in 1997, the
magnitude of the dengue problem has increased dramatically and has extended
geographically to many previously unaffected areas. It was then, and remains today,
the most important arthropod-borne viral disease of humans.
Activities undertaken by WHO regarding dengue are most recently guided at the global
policy level by World Health Assembly resolution WHA55.17 (adopted by the Fifty-fifth
World Health Assembly in 2002) and at the regional level by resolution CE140.R17 of
the Pan American Sanitary Conference (2007), resolution WPR/RC59.R6 of the WHO
Regional Committee for the Western Pacific (2008) and resolution SEA/RC61/R5 of
the WHO Regional Committee for South-East Asia (2008).
This new edition has been produced to make widely available to health practitioners,
laboratory personnel, those involved in vector control and other public health officials,
a concise source of information of worldwide relevance on dengue. The guidelines
provide updated practical information on the clinical management and delivery of
clinical services; vector management and delivery of vector control services; laboratory
diagnosis and diagnostic tests; and surveillance, emergency preparedness and response.
Looking ahead, some indications of new and promising avenues of research are also
described. Additional and more detailed specific guidance on the various specialist
areas related to dengue are available from other sources in WHO and elsewhere,
some of which are cited in the references.
The contributions of, and review by, many experts both within and outside WHO have
facilitated the preparation of this publication through consultative and peer review
processes. All contributors are gratefully acknowledged, a list of whom appears under
“Acknowledgements”. These guidelines are the result of collaboration between the
WHO Department of Control Neglected Tropical Diseases, the WHO Department of
Epidemic and Pandemic Alert and Response, and the Special Programme for Research
and Training in Tropical Diseases.
This publication is intended to contribute to prevention and control of the morbidity and
mortality associated with dengue and to serve as an authoritative reference source for
health workers and researchers. These guidelines are not intended to replace national
guidelines but to assist in the development of national or regional guidelines. They are
expected to remain valid for five years (until 2014), although developments in research
could change their validity, since many aspects of the prevention and control of dengue
are currently being investigated in a variety of studies. The guidelines contain the most
up-to-date information at the time of writing. However, the results of studies are being
published regularly and should be taken into account. To address this challenge, the
guide is also available on the Internet and will be updated regularly by WHO.
v
8. Dengue: Guidelines for diagnosis, treatment, prevention and control
METHODOLOGY
These guidelines were written using the following methodology:
1. Writing team
Each chapter was allocated to a WHO coordinator and at least one non-WHO lead
writer. The non-WHO lead writers received a small fee for their work. Declarations of
interest were obtained from all lead writers and no conflicting interests were declared.
The lead writers were chosen because of their expertise in the field and their willingness
to undertake the work.
Since this guide has the broad scope of all aspects of prevention and control of dengue,
the lead writers were selected for technical expertise in the areas of epidemiology,
pathogenesis and transmission, clinical aspects, vector control, laboratory aspects,
surveillance and response, and drug and vaccine development.
2. Peer review
All the chapters were submitted to peer review. The peer review groups were determined
by the WHO coordinator and the non-WHO lead writers of each chapter. The groups
consisted of five or more peer reviewers, who were not paid for their work. Declarations
of interest were obtained from all peer reviewers. For those peer reviewers with potential
conflicting interests, the interests are declared below.1
For each chapter, the process of reaching agreement on disputed issues differed. For
chapters 1, 3, 4 and 6, the comments of the peer reviewers were discussed electronically
within the group. Chapter 2 had a larger group whose members met for a consensus
group discussion. Chapter 5 required extensive discussion, but consensus was reached
without a consensus group meeting. Agreement on the chapter content was reached for
all the groups.
3. Use of evidence
For each chapter, items are referenced that (1) provide new data, (2) challenge current
practice, (3) describe ongoing research and (4) reflect key developments in knowledge
about dengue prevention and control.
Priority was given to systematic reviews when available. Additional literature searches
were conducted by the writing teams when items under 1--3 were identified, and
references from personal collections of experts were added when appropriate under 4.
The writing teams referred to the items under 1--4 in the text, and lists of references were
added at the end of each chapter.
1
Declared interests:
Chapter 1. Dr Anne Wilder Smith: principal investigator in dengue vaccine trial starting in 2009.
Chapter 4. Dr Mary Jane Cardosa: shareholder and director of company developing dengue diagnostic tests.
Chapter 6. Dr Robert Edelman: consultant for company involved in dengue vaccine research.
vi
9. Introduction, Methodology, Acknowledgements, Abbreviations, Preface
ACKNOWLEDGEMENTS
This new edition of the dengue guidelines would not have been possible without
the initiative, practical experience of many years of working in dengue, and writing
contribution of Dr Michael B. Nathan, now retired from the World Health Organization
(WHO).
Dr Axel Kroeger of the Special Programme for Research and Training in Tropical Diseases
(WHO/TDR) equally contributed to all parts of the guidelines.
Dr John Ehrenberg, Dr Chusak Prasittisuk and Dr Jose Luis San Martin, as WHO regional
advisers on dengue, contributed their unique experience to all chapters.
Dr Renu Dayal Drager (WHO) and Dr Jeremy Farrar (the Wellcome Trust) contributed
technical advice to several chapters.
Dr Raman Velayudhan (WHO) coordinated the finalization and publication of the guide
and advised on all the chapters.
Dr Olaf Horstick (WHO/TDR) assembled the evidence base, contributed to all chapters
and contributed to the finalization of the guide.
Special thanks are due to the editorial team of Mrs Karen Ciceri and Mr Patrick Tissot
at WHO.
The following individuals contributed to chapters as lead writers, advisers or peer
reviewers:
Chapter 1
Lead writers: Dr Michael B. Nathan, Dr Renu Dayal-Drager, Dr Maria Guzman.
Advisers and peer reviewers: Dr Olivia Brathwaite, Dr Scott Halstead, Dr Anand Joshi,
Dr Romeo Montoya, Dr Cameron Simmons, Dr Thomas Jaenisch, Dr Annelies Wilder-
Smith, Dr Mary Wilson.
Chapter 2
Lead writers: Dr Jacqueline Deen, Dr Lucy Lum, Dr Eric Martinez, Dr Lian Huat Tan.
Advisers and peer reviewers: Dr Jeremy Farrar, Dr Ivo Castelo Branco, Dr Efren Dimaano,
Dr Eva Harris, Dr Nguyen Hung, Dr Ida Safitri Laksono, Dr Jose Martinez, Dr Ernesto
Benjamín Pleites, Dr Rivaldo Venancio, Dr Elci Villegas, Dr Martin Weber, Dr Bridget
Wills.
Chapter 3
Lead writers: Dr Philip McCall, Dr Linda Lloyd, Dr Michael B. Nathan.
Advisers and peer reviewers: Dr Satish Appoo, Dr Roberto Barrera, Dr Robert Bos,
Dr Mohammadu Kabir Cham, Dr Gary G. Clark, Dr Christian Frederickson, Dr Vu Sinh
Nam, Dr Chang Moh Seng, Dr Tom W. Scott, Dr Indra Vithylingam, Dr Rajpal Yadav,
Dr André Yebakima, Dr Raman Velayudhan, Dr Morteza Zaim. vii
10. Dengue: Guidelines for diagnosis, treatment, prevention and control
Chapter 4
Lead writers: Dr Philippe Buchy, Dr Rosanna Peeling.
Advisers and peer reviewers: Dr Harvey Artsob, Dr Jane Cardosa, Dr Renu Dayal-
Drager, Dr Duane Gubler, Dr Maria Guzman, Dr Elizabeth Hunsperger, Dr Lucy Lum,
Dr Eric Martinez, Dr Jose Pelegrino, Dr Susana Vazquez.
Chapter 5
Lead writers: Dr Duane Gubler, Dr Gary G. Clark, Dr Renu Dayal-Drager, Dr Dana Focks,
Dr Axel Kroeger, Dr Angela Merianos, Dr Cathy Roth.
Advisers and peer reviewers: Dr Pierre Formenty, Dr Reinhard Junghecker, Dr Dominique
Legros, Dr Silvia Runge-Ranzinger, Dr José Rigau-Pérez.
Chapter 6
Lead writers: Dr Eva Harris, Dr Joachim Hombach, Dr Janis Lazdins-Held.
Advisers and peer reviewers: Dr Bruno Canard, Dr Anne Durbin, Dr Robert Edelman,
Dr Maria Guzman, Dr John Roehrig, Dr Subhash Vasudevan.
viii
11. Introduction, Methodology, Acknowledgements, Abbreviations, Preface
ABBREVIATIONS
a.i. ad interim
ADE antibody-dependent enhancement
ALT alanine amino transferase
AST aspartate amino transferase
BP blood pressure
BSL biosafety level
Bti Bacillus thuringiensis israelensis
CD4 cluster of differentiation 4, T helper cell surface glycoprotein
CD8 cluster of differentiation 8, T cell co-receptor transmembrane glycoprotein
CFR case-fatality rate
COMBI communication for behavioural impact
DALY disability-adjusted life years
DEET diethyl-meta-toluamide
DENCO Dengue and Control study (multi-country study)
DEN dengue
DDT dichlorodiphenyltrichloroethane
DF dengue fever
DHF dengue haemorrhagic fever
DNA deoxyribonucleic acid
DSS dengue shock syndrome
DT tablet for direct application
EC emulsifiable concentrate
ELISA enzyme-linked immunosorbent assay
E/M envelop/membrane antigen
FBC full blood count
Fc-receptor fragment, crystallisable region, a cell receptor
FRhL fetal rhesus lung cells
GAC E/M-specific capture IgG ELISA
GIS Geographical Information System
GOARN Global Outbreak Alert and Response Network
GPS global positioning system
GR granule
HI haemagglutination-inhibition
HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome
ICU intensive care unit
IEC information, education, communication
IgA immunoglobulin A
IgG immunoglobulin G
IgM immunoglobulin M
INF gamma interferon gamma ix
12. Dengue: Guidelines for diagnosis, treatment, prevention and control
IPCS International Programme on Chemical Safety
IR3535 3-[N-acetyl-N-butyl]-aminopropionic acid ethyl ester
ITM insecticide treated material
IV intravenous
LAV live attenuated vaccine
MAC-ELISA IgM antibody-capture enzyme-linked immunosorbent assay
MIA microsphere-based immunoassays
MoE Ministry of Education
MoH Ministry of Health
NAAT nucleic acid amplification test
NASBA nucleic acid sequence based amplification
NGO nongovernmental organization
NS non-structural protein
NSAID non-steroidal anti-inflammatory drugs
OD optical density
ORS oral rehydration solution
PAHO Pan American Health Organization
PCR polymerase chain reaction
PDVI Pediatric Dengue Vaccine Initiative
pH measure of the acidity or basicity of a solution
prM a region of the dengue genome
PRNT plaque reduction and neutralization test
RNA ribonucleic acid
RT-PCR reverse transcriptase-polymerase chain reaction
SC suspension concentrate
TNF alfa tumor necrosis factor alfa
T cells A group of lymphocytes important for cell-mediated immunity
TDR Special Programme for Research and Training in Tropical Diseases
WBC white blood cells
WG Water-dispersible granule
WHO World Health Organizaion
WP wettable powder
YF yellow fever
x
13. Chapter 1: Epidemiology, burden of disease and transmission
CHAPTER 1
CHAPTER 1
EPIDEMIOLOGY, BURDEN OF DISEASE
AND TRANSMISSION
1
16. Dengue: Guidelines for diagnosis, treatment, prevention and control
Figure 1.2 Average annual number of dengue fever (DF) and dengue haemorrhagic fever (DHF) cases
reported to WHO, and of countries reporting dengue, 1955–2007
1 000 000 70
925,896
900 000
60
800 000
Number of countries
700 000 50
Number of cases
600 000
40
500 000 479,848
30
400 000
300 000 295,554
20
200 000
122,174 10
100 000
908 15,497
0 0
1955-1959 1960-1969 1970-1979 1980-1989 1990-1999 2000-2007
Year
The following sections give an overview of the epidemiology and burden of disease in
the different WHO regions. All data are from country reports from the WHO regional
offices, unless referenced to a different source.
1.1.1 Dengue in Asia and the Pacific
Some 1.8 billion (more than 70%) of the population at risk for dengue worldwide live in
member states of the WHO South-East Asia Region and Western Pacific Region, which
bear nearly 75% of the current global disease burden due to dengue. The Asia Pacific
Dengue Strategic Plan for both regions (2008--2015) has been prepared in consultation
with member countries and development partners in response to the increasing threat
from dengue, which is spreading to new geographical areas and causing high mortality
during the early phase of outbreaks. The strategic plan aims to aid countries to reverse
the rising trend of dengue by enhancing their preparedness to detect, characterize and
contain outbreaks rapidly and to stop the spread to new areas.
4
17. Chapter 1: Epidemiology, burden of disease and transmission
1.1.1.1 Dengue in the WHO South-East Asia Region
Since 2000, epidemic dengue has spread to new areas and has increased in the
already affected areas of the region. In 2003, eight countries -- Bangladesh, India,
Indonesia, Maldives, Myanmar, Sri Lanka, Thailand and Timor-Leste -- reported dengue
cases. In 2004, Bhutan reported the country’s first dengue outbreak. In 2005, WHO’s
Global Outbreak Alert and Response Network (GOARN) responded to an outbreak with
a high case-fatality rate (3.55%) in Timor-Leste. In November 2006, Nepal reported
CHAPTER 1
indigenous dengue cases for the first time. The Democratic Peoples’ Republic of Korea is
the only country of the South-East Region that has no reports of indigenous dengue.
The countries of the region have been divided into four distinct climatic zones with
different dengue transmission potential. Epidemic dengue is a major public health
problem in Indonesia, Myanmar, Sri Lanka, Thailand and Timor-Leste which are in the
tropical monsoon and equatorial zone where Aedes aegypti is widespread in both urban
and rural areas, where multiple virus serotypes are circulating, and where dengue is a
leading cause of hospitalization and death in children. Cyclic epidemics are increasing
in frequency and in-country geographic expansion is occurring in Bangladesh, India
and Maldives -- countries in the deciduous dry and wet climatic zone with multiple virus
serotypes circulating. Over the past four years, epidemic dengue activity has spread to
Bhutan and Nepal in the sub-Himalayan foothills.
Reported case fatality rates for the region are approximately 1%, but in India, Indonesia
and Myanmar, focal outbreaks away from the urban areas have reported case-fatality
rates of 3--5%.
In Indonesia, where more than 35% of the country’s population lives in urban areas,
150 000 cases were reported in 2007 (the highest on record) with over 25 000 cases
reported from both Jakarta and West Java. The case-fatality rate was approximately
1%.
In Myanmar in 2007 the states/divisions that reported the highest number of cases
were Ayayarwaddy, Kayin, Magway, Mandalay, Mon, Rakhine, Sagaing, Tanintharyi
and Yangon. From January to September 2007, Myanmar reported 9578 cases. The
reported case-fatality rate in Myanmar is slightly above 1%.
In Thailand, dengue is reported from all four regions: Northern, Central, North-Eastern
and Southern. In June 2007, outbreaks were reported from Trat province, Bangkok,
Chiangrai, Phetchabun, Phitsanulok, Khamkaeng Phet, Nakhon Sawan and Phit Chit. A
total of 58 836 cases were reported from January to November 2007. The case-fatality
rate in Thailand is below 0.2%.
Dengue prevention and control will be implemented through the Bi-regional Dengue
Strategy (2008--2015) of the WHO South-East Asia and Western Pacific regions. This
consists of six elements: (i) dengue surveillance, (ii) case management, (iii) outbreak
response, (iv) integrated vector management, (v) social mobilization and communication
for dengue and (vi) dengue research (a combination of both formative and operational
research). The strategy has been endorsed by resolution SEA/RC61/R5 of the WHO
Regional Committee for South-East Asia in 2008 (4).
5
18. Dengue: Guidelines for diagnosis, treatment, prevention and control
1.1.1.2 Dengue in the WHO Western Pacific Region
Dengue has emerged as a serious public health problem in the Western Pacific Region
(5). Since the last major pandemic in 1998, epidemics have recurred in much of
the area. Lack of reporting remains one of the most important challenges in dengue
prevention and control.
Between 2001 and 2008, 1 020 333 cases were reported in Cambodia, Malaysia,
Philippines, and Viet Nam -- the four countries in the Western Pacific Region with the
highest numbers of cases and deaths. The combined death toll for these four countries
was 4798 (official country reports). Compared with other countries in the same region,
the number of cases and deaths remained highest in Cambodia and the Philippines in
2008. Overall, case management has improved in the Western Pacific Region, leading
to a decrease in case fatality rates.
Dengue has also spread throughout the Pacific Island countries and areas. Between
2001 and 2008, the six most affected Pacific island countries and areas were French
Polynesia (35 869 cases), New Caledonia (6836 cases), Cook Islands (3735
cases), American Samoa (1816 cases), Palau (1108 cases) and the Federal States of
Micronesia (664 cases). The total number of deaths for the six island countries was 34
(official country reports). Although no official reports have been submitted to WHO by
Kiribati, the country did experience a dengue outbreak in 2008, reporting a total of
837 cases and causing great concern among the national authorities and among some
of the other countries in the region.
Historically, dengue has been reported predominantly among urban and peri-urban
populations where high population density facilitates transmission. However, evidence
from recent outbreaks, as seen in Cambodia in 2007, suggests that they are now
occurring in rural areas.
Implementing the Bi-regional Dengue Strategy for Asia and the Pacific (2008--2015) is
a priority following endorsement by the 2008 resolution WPR/RC59.R6 of the WHO
Regional Committee for the Western Pacific (6).
1.1.2 Dengue in the Americas
Interruption of dengue transmission in much the WHO Region of the Americas resulted
from the Ae. aegypti eradication campaign in the Americas, mainly during the 1960s
and early 1970s. However, vector surveillance and control measures were not sustained
and there were subsequent reinfestations of the mosquito, followed by outbreaks in the
Caribbean, and in Central and South America (7). Dengue fever has since spread with
cyclical outbreaks occurring every 3--5 years. The biggest outbreak occurred in 2002
with more than 1 million reported cases.
From 2001 to 2007, more than 30 countries of the Americas notified a total of 4 332
731 cases of dengue (8). The number of cases of dengue haemorrhagic fever (DHF)
in the same period was 106 037. The total number of dengue deaths from 2001 to
6
19. Chapter 1: Epidemiology, burden of disease and transmission
2007 was 1299, with a DHF case fatality rate of 1.2%. The four serotypes of the
dengue virus (DEN-1, DEN-2, DEN-3 and DEN-4) circulate in the region. In Barbados,
Colombia, Dominican Republic, El Salvador, Guatemala, French Guyana, Mexico,
Peru, Puerto Rico and Venezuela, all four serotypes were simultaneously identified in one
year during this period.
By subregion of the Americas, dengue is characterized as described below. All data
are from the Pan American Health Organization (PAHO) (8).
CHAPTER 1
The Southern Cone countries
Argentina, Brazil, Chile, Paraguay and Uruguay are located in this subregion. In the
period from 2001 to 2007, 64.6% (2 798 601) of all dengue cases in the Americas
were notified in this subregion, of which 6733 were DHF with a total of 500 deaths.
Some 98.5% of the cases were notified by Brazil, which also reports the highest case
fatality rate in the subregion. In the subregion, DEN-1, -2 and -3 circulate.
Andean countries
This subregion includes Bolivia, Colombia, Ecuador, Peru and Venezuela, and
contributed 19% (819 466) of dengue cases in the Americas from 2001 to 2007. It is
the subregion with the highest number of reported DHF cases, with 58% of all cases (61
341) in the Americas, and 306 deaths. Colombia and Venezuela have most cases in
the subregion (81%), and in Colombia there were most dengue deaths (225, or 73%).
In Colombia, Peru and Venezuela all four dengue serotypes were identified.
Central American countries and Mexico
During 2001–2007, a total of 545 049 cases, representing 12.5% of dengue in the
Americas, was reported, with 35 746 cases of DHF and 209 deaths. Nicaragua had
64 deaths (31%), followed by Honduras with 52 (25%) and Mexico with 29 (14%).
Costa Rica, Honduras and Mexico reported the highest number of cases in this period.
DEN-1, -2 and -3 were the serotypes most frequently reported.
Caribbean countries
In this subregion 3.9% (168 819) of the cases of dengue were notified, with 2217 DHF
cases and 284 deaths. Countries with the highest number of dengue cases in the Latin
Caribbean were Cuba, Puerto Rico and the Dominican Republic, whereas in the English
and French Caribbean, Martinique, Trinidad and Tobago and French Guiana reported
the highest numbers of cases. The Dominican Republic reported 77% of deaths (220)
during the period 2001--2007. All four serotypes circulate in the Caribbean area, but
predominantly DEN-1 and -2.
North American countries
The majority of the notified cases of dengue in Canada and the United States are
persons who had travelled to endemic areas in Asia, the Caribbean, or Central or South
America (9). From 2001 to 2007, 796 cases of dengue were reported in the United
States, the majority imported. Nevertheless, outbreaks of dengue in Hawaii have been
reported, and there were outbreaks sporadically with local transmission in Texas at the
border with Mexico (10,11).
7
20. Dengue: Guidelines for diagnosis, treatment, prevention and control
The Regional Dengue Programme of PAHO focuses public policies towards a multisectoral
and interdisciplinary integration. This allows the formulation, implementation, monitoring
and evaluation of national programmes through the Integrated Management Strategy
for Prevention and Control of Dengue (EGI-dengue, from its acronym in Spanish). This
has six key components: (i) social communication (using Communication for Behavioural
Impact (COMBI)), (ii) entomology, (iii) epidemiology, (iv) laboratory diagnosis, (v) case
management and (vi) environment. This strategy has been endorsed by PAHO resolutions
(12–15). Sixteen countries and three subregions (Central America, Mercosur and the
Andean subregion) agreed to use EGI-dengue as a strategy and are in the process of
implementation.
1.1.3 Dengue in the WHO African Region
Although dengue exists in the WHO African Region, surveillance data are poor.
Outbreak reports exist, although they are not complete, and there is evidence that
dengue outbreaks are increasing in size and frequency (16). Dengue is not officially
reported to WHO by countries in the region. Dengue-like illness has been recorded
in Africa though usually without laboratory confirmation and could be due to infection
with dengue virus or with viruses such as chikungunya that produce similar clinical
symptoms.
Dengue has mostly been documented in Africa from published reports of serosurveys
or from diagnosis in travellers returning from Africa, and dengue cases from countries
in Sub-Saharan Africa. A serosurvey (17) suggests that dengue existed in Africa as far
back as 1926--1927, when the disease caused an epidemic in Durban, South Africa.
Cases of dengue imported from India were detected in the 1980s (18).
For eastern Africa, the available evidence so far indicates that DEN-1, -2 and -3 appear to
be common causes of acute fever. Examples of this are outbreaks in the Comoros in various
years (1948, 1984 and 1993, DEN-1 and -2) (19) and Mozambique (1984--1985,
DEN-3) (20).
In western Africa in the 1960s, DEN-1, -2 and -3 were isolated for the first time from
samples taken from humans in Nigeria (21). Subsequent dengue outbreaks have been
reported from different countries, as for example from Burkina Faso (1982, DEN-2) (22)
and Senegal (1999, DEN-2) (23). Also DEN-2 and DEN-3 cases were confirmed in
Côte d’Ivoire in 2006 and 2008.
Despite poor surveillance for dengue in Africa, it is clear that epidemic dengue fever
caused by all four dengue serotypes has increased dramatically since 1980, with most
epidemics occurring in eastern Africa, and to a smaller extent in western Africa, though
this situation may be changing in 2008.
While dengue may not appear to be a major public health problem in Africa compared
to the widespread incidence of malaria and HIV/AIDS, the increasing frequency
and severity of dengue epidemics worldwide calls for a better understanding of the
epidemiology of dengue infections with regard to the susceptibility of African populations
to dengue and the interference between dengue and the other major communicable
8 diseases of the continent.
21. Chapter 1: Epidemiology, burden of disease and transmission
1.1.4 Dengue in the WHO Eastern Mediterranean Region (Figure 1.3)
Outbreaks of dengue have been documented in the Eastern Mediterranean Region
possibly as early as 1799 in Egypt (24). The frequency of reported outbreaks continue
to increase, with outbreaks for example in Sudan (1985, DEN-1 and -2) (25) and in
Djibouti (1991, DEN-2) (26).
Recent outbreaks of suspected dengue have been recorded in Pakistan, Saudi Arabia,
CHAPTER 1
Sudan and Yemen, 2005--2006 (24). In Pakistan, the first confirmed outbreak of DHF
occurred in 1994. A DEN-3 epidemic with DHF was first reported in 2005 (27).
Since then, the expansion of dengue infections with increasing frequency and severity
has been reported from large cities in Pakistan as far north as the North-West Frontier
Province in 2008. Dengue is now a reportable disease in Pakistan. A pertinent issue
for this region is the need to better understand the epidemiological situation of dengue
in areas that are endemic for Crimean-Congo haemorrhagic fever and co-infections of
these pathogens.
Yemen is also affected by the increasing frequency and geographic spread of epidemic
dengue, and the number of cases has risen since the major DEN-3 epidemic that
occurred in the western al-Hudeidah governorate in 2005. In 2008 dengue affected
the southern province of Shabwa.
Since the first case of DHF died in Jeddah in 1993, Saudi Arabia has reported three
major epidemics: a DEN-2 epidemic in 1994 with 469 cases of dengue, 23 cases of
DHF, two cases of dengue shock syndrome (DSS) and two deaths; a DEN-1 epidemic
in 2006 with 1269 cases of dengue, 27 cases of DHF, 12 cases of DSS and six
Figure 1.3 Outbreaks of dengue fever in the WHO Eastern Mediterranean Region, 1994–2005
Sudan (No data)
Djibouti (1991-1992, DEN-2) Somalia (1982, 1993, DEN-2)
DEN-2:
1994: 673 suspected cases, 289 confirmed cases
Al-Hudaydah, Mukkala, Shaabwa
1995: 136 suspected cases, 6 confirmed cases
(1994, DEN-3, no data);
1996: 57 suspected cases, 2 confirmed cases
1997: 62 suspected cases, 15 confirmed cases
Al-Hudaydah, Yemen
1998: 31 suspected cases, 0 confirmed cases (September 2000, DEN-2, 653 suspected cases, 80 deaths (CFR = 12%));
1999: 26 suspected cases, 3 confirmed cases Al-Hudaydah, Yemen
2000: 17 suspected cases, 0 confirmed cases (March 2004, 45 suspected cases, 2 deaths);
2001: 7 suspected cases, 0 confirmed cases Al-Hudaydah, Mukkala
2005: 32 suspected (confirmed) (March 2005, 403 suspected cases, 2 deaths);
9
22. Dengue: Guidelines for diagnosis, treatment, prevention and control
deaths; and a DEN-3 epidemic in 2008 with 775 cases of dengue, nine cases of
DHF, four cases of DSS and four deaths. A pertinent issue for the IHR is that Jeddah is
a Haj entry point -- as well as being the largest commercial port in the country, and the
largest city with the busiest airport in the western region -- with large numbers of people
coming from high-burden dengue countries such as Indonesia, Malaysia and Thailand,
in addition to the dengue-affected countries of the region.
1.1.5 Dengue in other regions
As described above, dengue is now endemic in all WHO regions except the WHO
European Region. Data available for the European region (http://data.euro.who.int/
cisid/) indicate that most cases in the region have been reported by European Union
member states, either as incidents in overseas territories or importations from endemic
countries. [See also a report from the European Centre for Disease Prevention and
Control (28)]. However, in the past, dengue has been endemic in some Balkan and
Mediterranean countries of the region, and imported cases in the presence of known
mosquito vectors (e.g. Aedes albopictus) cannot exclude future disease spread.
Globally, reporting on dengue cases shows cyclical variation with high epidemic years
and non-epidemic years. Dengue often presents in the form of large outbreaks. There is,
however, also a seasonality of dengue, with outbreaks occurring in different periods of
the year. This seasonality is determined by peak transmission of the disease, influenced
by characteristics of the host, the vector and the agent.
1.1.6 Dengue case classification
Dengue has a wide spectrum of clinical presentations, often with unpredictable clinical
evolution and outcome. While most patients recover following a self-limiting non-severe
clinical course, a small proportion progress to severe disease, mostly characterized by
plasma leakage with or without haemorrhage. Intravenous rehydration is the therapy
of choice; this intervention can reduce the case fatality rate to less than 1% of severe
cases. The group progressing from non-severe to severe disease is difficult to define, but
this is an important concern since appropriate treatment may prevent these patients from
developing more severe clinical conditions.
Triage, appropriate treatment, and the decision as to where this treatment should be
given (in a health care facility or at home) are influenced by the case classification for
dengue. This is even more the case during the frequent dengue outbreaks worldwide,
where health services need to be adapted to cope with the sudden surge in demand.
Changes in the epidemiology of dengue, as described in the previous sections, lead
to problems with the use of the existing WHO classification. Symptomatic dengue virus
infections were grouped into three categories: undifferentiated fever, dengue fever (DF)
and dengue haemorrhagic fever (DHF). DHF was further classified into four severity
grades, with grades III and IV being defined as dengue shock syndrome (DSS) (29).
There have been many reports of difficulties in the use of this classification (30–32),
which were summarized in a systematic literature review (33). Difficulties in applying
10
the criteria for DHF in the clinical situation, together with the increase in clinically
23. Chapter 1: Epidemiology, burden of disease and transmission
severe dengue cases which did not fulfil the strict criteria of DHF, led to the request
for the classification to be reconsidered. Currently the classification into DF/DHF/DSS
continues to be widely used. (29)
A WHO/TDR-supported prospective clinical multicentre study across dengue-endemic
regions was set up to collect evidence about criteria for classifying dengue into levels of
severity. The study findings confirmed that, by using a set of clinical and/or laboratory
parameters, one sees a clear-cut difference between patients with severe dengue and
CHAPTER 1
those with non-severe dengue. However, for practical reasons it was desirable to split
the large group of patients with non-severe dengue into two subgroups -- patients with
warning signs and those without them. Criteria for diagnosing dengue (with or without
warning signs) and severe dengue are presented in Figure 1.4. It must be kept in mind
that even dengue patients without warning signs may develop severe dengue.
Expert consensus groups in Latin America (Havana, Cuba, 2007), South-East Asia
(Kuala Lumpur, Malaysia, 2007), and at WHO headquarters in Geneva, Switzerland
in 2008 agreed that:
“dengue is one disease entity with different clinical presentations and often with
unpredictable clinical evolution and outcome”;
the classification into levels of severity has a high potential for being of practical use in
the clinicians’ decision as to where and how intensively the patient should be observed
and treated (i.e. triage, which is particularly useful in outbreaks), in more consistent
reporting in the national and international surveillance system, and as an end-point
measure in dengue vaccine and drug trials.
Figure 1.4 Suggested dengue case classification and levels of severity
DENGUE ± WARNING SIGNS SEVERE DENGUE
1. Severe plasma leakage
with warning
signs 2. Severe haemorrhage
without 3.Severe organ impairment
CRITERIA FOR DENGUE ± WARNING SIGNS CRITERIA FOR SEVERE DENGUE
Probable dengue Warning signs* Severe plasma leakage
live in /travel to dengue endemic area. • Abdominal pain or tenderness leading to:
Fever and 2 of the following criteria: • Persistent vomiting • Shock (DSS)
• Nausea, vomiting • Clinical fluid accumulation
• Fluid accumulation with respiratory
• Rash • Mucosal bleed distress
• Aches and pains • Lethargy, restlessness
Severe bleeding
• Tourniquet test positive • Liver enlargment 2 cm
as evaluated by clinician
• Leukopenia • Laboratory: increase in HCT
• Any warning sign concurrent with rapid decrease Severe organ involvement
in platelet count • Liver: AST or ALT =1000
• CNS: Impaired consciousness
Laboratory-confirmed dengue *(requiring strict observation and medical
• Heart and other organs
(important when no sign of plasma leakage) intervention)
11
24. Dengue: Guidelines for diagnosis, treatment, prevention and control
This model for classifying dengue has been suggested by an expert group (Geneva,
Switzerland, 2008) and is currently being tested in 18 countries by comparing its
performance in practical settings to the existing WHO case classification. The process
will be finalized in 2010. For practical reasons this guide adapts the distinction between
dengue and severe dengue.
Additionally the guide uses three categories for case management (A, B, C) (Chapter 2).
1.2 BURDEN OF DISEASE
Dengue inflicts a significant health, economic and social burden on the populations of
endemic areas. Globally the estimated number of disability-adjusted life years (DALYs)
lost to dengue in 2001 was 528 (34). In Puerto Rico, an estimated yearly mean of 580
DALYs per million population were lost to dengue between 1984 and 1994 -- similar
to the cumulative total of DALYs lost to malaria, tuberculosis, intestinal helminths and the
childhood disease cluster in all of Latin America and the Caribbean (35).
The number of cases reported annually to WHO ranged from 0.4 to 1.3 million
in the decade 1996 -- 2005. As an infectious disease, the number of cases varies
substantially from year to year. Underreporting and misdiagnoses are major obstacles to
understanding the full burden of dengue (36).
Available data from South-East Asia is largely derived from hospitalized cases among
children but the burden due to uncomplicated dengue fever is also considerable. In a
prospective study of schoolchildren in northern Thailand the mean annual burden of
dengue over a five-year period was 465.3 DALYs per million, with non-hospitalized
patients with dengue illness contributing 44 -- 73% of the total (37).
Studies on the cost of dengue were conducted in eight countries in 2005-2006: five
in the Americas (Brazil, El Salvador, Guatemala, Panama, Venezuela) and three in
Asia (Cambodia, Malaysia, Thailand) (38). As dengue also affected other household
members who helped care for the dengue patient, an average episode represented
14.8 lost days for ambulatory patients and 18.9 days for hospitalized patients. The
overall cost of a non-fatal ambulatory case averaged US$ 514, while the cost of a
non-fatal hospitalized case averaged US$ 1491. On average, a hospitalized case
of dengue cost three times what an ambulatory case costs. Combining the ambulatory
and hospitalized patients and factoring in the risk of death, the overall cost of a dengue
case is US$ 828. Merging this number with the average annual number of officially
reported dengue cases from the eight countries studied in the period 2001 -- 2005
(532 000 cases) gives a cost of officially reported dengue of US$ 440 million. This
very conservative estimate ignores not only the underreporting of cases but also the
substantial costs associated with dengue surveillance and vector control programmes.
This study showed that a treated dengue episode imposes substantial costs on both the
health sector and the overall economy. If a vaccine were able to prevent much of this
burden, the economic gains would be substantial.
12
25. Chapter 1: Epidemiology, burden of disease and transmission
Children are at a higher risk of severe dengue (39). Intensive care is required for severely
ill patients, including intravenous fluids, blood or plasma transfusion and medicines.
Dengue afflicts all levels of society but the burden may be higher among the poorest who
grow up in communities with inadequate water supply and solid waste infrastructure,
and where conditions are most favourable for multiplication of the main vector, Ae.
aegypti.
CHAPTER 1
1.3 DENGUE IN INTERNATIONAL TRAVEL
Travellers play an essential role in the global epidemiology of dengue infections, as
viraemic travellers carry various dengue serotypes and strains into areas with mosquitoes
that can transmit infection (40). Furthermore, travellers perform another essential service
in providing early alerts to events in other parts of the world. Travellers often transport
the dengue virus from areas in tropical developing countries, where limited laboratory
facilities exist, to developed countries with laboratories that can identify virus serotypes
(41). Access to research facilities makes it possible to obtain more detailed information
about a virus, including serotype and even sequencing, when that information would be
valuable. Systematic collection of clinical specimens and banking of serum or isolates
may have future benefits as new technologies become available.
From the data collected longitudinally over a decade by the GeoSentinel Surveillance
Network (www.geosentinel.org) it was possible, for example, to examine month-by-
month morbidity from a sample of 522 cases of dengue as a proportion of all diagnoses
in 24 920 ill returned travellers seen at 33 surveillance sites. Travel-related dengue
demonstrated a defined seasonality for multiple regions (South-East Asia, South Central
Asia, Caribbean, South America) (42).
Information about dengue in travellers, using sentinel surveillance, can be shared rapidly
to alert the international community to the onset of epidemics in endemic areas where
there is no surveillance and reporting of dengue, as well as the geographic spread of
virus serotypes and genotypes to new areas which increases the risk of severe dengue.
The information can also assist clinicians in temperate regions -- most of whom are not
trained in clinical tropical diseases -- to be alert for cases of dengue fever in ill returned
travellers. The clinical manifestations and complications of dengue can also be studied
in travellers (most of them adult and non-immune) as dengue may present differently
compared with the endemic population (most of them in the paediatric age group and
with pre-existing immunity). The disadvantage of such sentinel surveillance, however, is
the lack of a denominator: true risk incidence cannot be determined. An increase in
cases in travellers could be due to increased travel activity to dengue endemic areas,
for instance.
13
26. Dengue: Guidelines for diagnosis, treatment, prevention and control
1.4 TRANSMISSION
1.4.1 The virus
Dengue virus (DEN) is a small single-stranded RNA virus comprising four distinct serotypes
(DEN-1 to -4). These closely related serotypes of the dengue virus belong to the genus
Flavivirus, family Flaviviridae.
The mature particle of the dengue virus is spherical with a diameter of 50nm containing
multiple copies of the three structural proteins, a host-derived membrane bilayer and a
single copy of a positive-sense, single-stranded RNA genome. The genome is cleaved
by host and viral proteases in three structural proteins (capsid, C, prM, the precursor of
membrane, M, protein and envelope, E) and seven nonstructural proteins (NS).
Distinct genotypes or lineages (viruses highly related in nucleotide sequence) have
been identified within each serotype, highlighting the extensive genetic variability of
the dengue serotypes. Purifying selection appears to be a dominant theme in dengue
viral evolution, however, such that only viruses that are “fit” for both human and vector
are maintained. Among them, “Asian” genotypes of DEN-2 and DEN-3 are frequently
associated with severe disease accompanying secondary dengue infections (43–45).
Intra-host viral diversity (quasispecies) has also been described in human hosts.
1.4.2 The vectors
The various serotypes of the dengue virus are transmitted to humans through the bites
of infected Aedes mosquitoes, principally Ae. aegypti. This mosquito is a tropical
and subtropical species widely distributed around the world, mostly between latitudes
35 0N and 35 0S. These geographical limits correspond approximately to a winter
isotherm of 10 0C. Ae. aegypti has been found as far north as 45 0N, but such
invasions have occurred during warmer months and the mosquitoes have not survived
the winters. Also, because of lower temperatures, Ae. aegypti is relatively uncommon
above 1000 metres. The immature stages are found in water-filled habitats, mostly in
artificial containers closely associated with human dwellings and often indoors. Studies
suggest that most female Ae. aegypti may spend their lifetime in or around the houses
where they emerge as adults. This means that people, rather than mosquitoes, rapidly
move the virus within and between communities. Dengue outbreaks have also been
attributed to Aedes albopictus, Aedes polynesiensis and several species of the Aedes
scutellaris complex. Each of these species has a particular ecology, behaviour and
geographical distribution. In recent decades Aedes albopictus has spread from Asia to
Africa, the Americas and Europe, notably aided by the international trade in used tyres
in which eggs are deposited when they contain rainwater. The eggs can remain viable
for many months in the absence of water (Chapter 3).
14
27. Chapter 1: Epidemiology, burden of disease and transmission
1.4.2 The host
After an incubation period of 4--10 days, infection by any of the four virus serotypes
can produce a wide spectrum of illness, although most infections are asymptomatic
or subclinical (Chapter 2). Primary infection is thought to induce lifelong protective
immunity to the infecting serotype (46). Individuals suffering an infection are protected
from clinical illness with a different serotype within 2--3 months of the primary infection
but with no long-term cross-protective immunity.
CHAPTER 1
Individual risk factors determine the severity of disease and include secondary infection,
age, ethnicity and possibly chronic diseases (bronchial asthma, sickle cell anaemia and
diabetes mellitus). Young children in particular may be less able than adults to compensate
for capillary leakage and are consequently at greater risk of dengue shock.
Seroepidemiological studies in Cuba and Thailand consistently support the role of
secondary heterotypic infection as a risk factor for severe dengue, although there are
a few reports of severe cases associated with primary infection (47–50). The time
interval between infections and the particular viral sequence of infections may also be of
importance. For instance, a higher case fatality rate was observed in Cuba when DEN-
2 infection followed a DEN-1 infection after an interval of 20 years compared to an
interval of four years. Severe dengue is also regularly observed during primary infection
of infants born to dengue-immune mothers. Antibody-dependent enhancement (ADE) of
infection has been hypothesized (51,52) as a mechanism to explain severe dengue in
the course of a secondary infection and in infants with primary infections. In this model,
non-neutralizing, cross-reactive antibodies raised during a primary infection, or acquired
passively at birth, bind to epitopes on the surface of a heterologous infecting virus and
facilitate virus entry into Fc-receptor-bearing cells. The increased number of infected cells
is predicted to result in a higher viral burden and induction of a robust host immune
response that includes inflammatory cytokines and mediators, some of which may
contribute to capillary leakage. During a secondary infection, cross-reactive memory T
cells are also rapidly activated, proliferate, express cytokines and die by apoptosis in a
manner that generally correlates with overall disease severity. Host genetic determinants
might influence the clinical outcome of infection (53,54), though most studies have been
unable to adequately address this issue. Studies in the American region show the rates
of severe dengue to be lower in individuals of African ancestry than those in other ethnic
groups. (54)
The dengue virus enters via the skin while an infected mosquito is taking a bloodmeal.
During the acute phase of illness the virus is present in the blood and its clearance
from this compartment generally coincides with defervescence. Humoral and cellular
immune responses are considered to contribute to virus clearance via the generation
of neutralizing antibodies and the activation of CD4+ and CD8+ T lymphocytes. In
addition, innate host defence may limit infection by the virus. After infection, serotype-
specific and cross-reactive antibodies and CD4+ and CD8+ T cells remain measurable
for years.
Plasma leakage, haemoconcentration and abnormalities in homeostasis characterize
severe dengue. The mechanisms leading to severe illness are not well defined but the
immune response, the genetic background of the individual and the virus characteristics
may all contribute to severe dengue. 15
28. Dengue: Guidelines for diagnosis, treatment, prevention and control
Recent data suggest that endothelial cell activation could mediate plasma leakage
(55,56). Plasma leakage is thought to be associated with functional rather than
destructive effects on endothelial cells. Activation of infected monocytes and T cells, the
complement system and the production of mediators, monokines, cytokines and soluble
receptors may also be involved in endothelial cell dysfunction.
Thrombocytopenia may be associated with alterations in megakaryocytopoieses by
the infection of human haematopoietic cells and impaired progenitor cell growth,
resulting in platelet dysfunction (platelet activation and aggregation), increased
destruction or consumption (peripheral sequestration and consumption). Haemorrhage
may be a consequence of the thrombocytopenia and associated platelet dysfunction
or disseminated intravascular coagulation. In summary, a transient and reversible
imbalance of inflammatory mediators, cytokines and chemokines occurs during severe
dengue, probably driven by a high early viral burden, and leading to dysfunction of
vascular endothelial cells, derangement of the haemocoagulation system then to plasma
leakage, shock and bleeding.
1.4.4 Transmission of the dengue virus
Humans are the main amplifying host of the virus. Dengue virus circulating in the blood of
viraemic humans is ingested by female mosquitoes during feeding. The virus then infects
the mosquito mid-gut and subsequently spreads systemically over a period of 8--12 days.
After this extrinsic incubation period, the virus can be transmitted to other humans during
subsequent probing or feeding. The extrinsic incubation period is influenced in part
by environmental conditions, especially ambient temperature. Thereafter the mosquito
remains infective for the rest of its life. Ae. aegypti is one of the most efficient vectors
for arboviruses because it is highly anthropophilic, frequently bites several times before
completing oogenesis, and thrives in close proximity to humans. Vertical transmission
(transovarial transmission) of dengue virus has been demonstrated in the laboratory
but rarely in the field. The significance of vertical transmission for maintenance of the
virus is not well understood. Sylvatic dengue strains in some parts of Africa and Asia
may also lead to human infection, causing mild illness. Several factors can influence
the dynamics of virus transmission -- including environmental and climate factors, host-
pathogen interactions and population immunological factors. Climate directly influences
the biology of the vectors and thereby their abundance and distribution; it is consequently
an important determinant of vector-borne disease epidemics.
16
29. Chapter 1: Epidemiology, burden of disease and transmission
REFERENCES
1. WHO. Dengue and dengue haemorrhagic fever. Factsheet No 117, revised May
2008. Geneva, World Health Organization, 2008 (http://www.who.int/mediacentre/
factsheets/fs117/en/).
2. WHO. Dengue fever and dengue haemorrhagic fever prevention and control. World
CHAPTER 1
Health Assembly Resolution WHA55.17, adopted by the 55th World Health Assembly,
2002 (http://www.who.int/gb/ebwha/pdf_files/WHA55/ewha5517.pdf).
3. WHO. Revision of the International Health Regulations. World Health Assembly
Resolution WHA58.3, adopted by the 58th World Health Assembly, 2005 (http://
www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_3-en.pdf).
4. WHO/SEARO. Concrete measure key in controlling dengue in South East Asia.
Press Release SEA/PR/1479. New Delhi, World Health Organization Regional Office
for South-East Asia, 2008. (http://www.searo.who.int/EN/Section316/Section503/
Section2463_14619.htm).
5. WHO. Denguenet in India. Weekly Epidemiological Record, 2004, 79(21):201--203
(http://whqlibdoc.who.int/wer/WHO_WER_2004/79_201-204(no21).pdf).
6. WHO/WPRO. Dengue fever and dengue haemorrhagic fever prevention and
control. Regional Committee resolution WPR/RC59.R6, adopted by the WHO Regional
Committee for the Western Pacific, 2008
(http://www.wpro.who.int/rcm/en/rc59/rc_resolutions/WPR_RC59_R6.htm).
7. PAHO. Plan continental de ampliación e intensificación del combate al Aedes
aegypti. Informe de un grupo de trabajo, Caracas, Venezuela. Abril 1997. Washington,
DC, Pan American Health Organization, 1997 (Document OPS/HCP/HCT/90/97,
in Spanish) (http://www.paho.org/Spanish/AD/DPC/CD/doc407.pdf).
8. PAHO. Number of reported cases of dengue and dengue hemorrhagic fever (DHF),
Region of the Americas (by country and subregion). Washington, DC, Pan American Health
Organization, 2008. (http://www.paho.org/english/ad/dpc/cd/dengue.htm).
9. Centers for Disease Control and Prevention. Travel-associated dengue -- United
States, 2005. Morbidity and Mortality Weekly Report, 2006, 55(25):700--702.
10. Ramos MM et al. Dengue Serosurvey Working Group. Epidemic dengue and
dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based
seroepidemiologic survey, December 2005. American Journal of Tropical Medicine
and Hygiene, 2008, 78(3):364--369.
11. Centers for Disease Control and Prevention. Dengue hemorrhagic fever -- U.S.-
Mexico border, 2005. Morbidity and Mortality Weekly Report, 2007, 56(31):785--
789. Erratum in: Morbidity and Mortality Weekly Report, 2007, 56(32):822.
17
30. Dengue: Guidelines for diagnosis, treatment, prevention and control
12. PAHO. Dengue and dengue hemorrhagic fever. Regional Committee resolution
CD43.R4, adopted at the 53rd session of the Regional Committee for the Americas,
43rd Directing Council. Washington, DC, Pan American Health Organization, 2001
(http://www.paho.org/english/hcp/hct/vbd/new-generation-resolutions.pdf).
13. PAHO. Dengue. Regional Committee resolution CD44.R9, adopted at the 55th
session of the Regional Committee for the Americas, 44th Directing Council. Washington,
DC, Pan American Health Organization, 2003
(http://www.paho.org/english/gov/cd/cd44-r9-e.pdf).
14. PAHO. Grupo de Trabajo sobre Dengue. Estrategia de Gestión Integrada para la
prevención y control del dengue en la Región de las Américas. 2.ª versión. Santa Cruz
de la Sierra, Bolivia. Pan American Health Organization, 2003 (Document OPS/
HDM/CD/440.07, in Spanish).
15. PAHO. Pan American Health Organization. Prevención y control del dengue en las
Américas. Resolución CSP27.R15. 27. a Conferencia Sanitaria Panamericana CSP27.
R15 (Esp.) 1--5 de octubre de 2007 (in Spanish).
16. Nathan MB, Dayal-Drager R. Recent epidemiological trends, the global strategy
and public health advances in dengue. Working paper 3.1 in: Report of the Scientific
Working Group meeting on Dengue, Geneva, 1–5 October 2006. Geneva, World
Health Organization, Special Programme for Research and Training in Tropical Diseases,
2007 (pp 29--34) (Document TDR/SWG/07).
17. Kokernot RH, Smithburn KC, Weinbren MP. Neutralising antibodies to arthropod-
borne viruses in human and animals in the Union of South Africa.
Journal of Immunology, 1956, 77:313–322.
18. Blackburn NK, Rawal R. Dengue fever imported from India: a report of 3 cases.
South African Medical Journal, 1987, 21:386–287.
19. Boisier P et al. Dengue 1 epidemic in the Grand Comoro Island (Federal Islamic
Republic of the Comores), March-May 1993. Annales de la Société Belge de Médecine
Tropicale, 1993, 74:217–229.
20. Gubler DJ et al. Dengue 3 Virus Transmission in Africa. American Journal of Tropical
Medicine and Hygiene, 1986, 35(6):1280--1284.
21. Carey DE et al. Dengue virus from febrile patients in Nigeria 1964–68. Lancet,
1971, 1:105–106.
22. Gonzalez JP et al. Dengue in Burkina Faso: seasonal epidemics in the urban area
of Ouagadougu. Bulletin de la Société de pathologie exotique et de ses filiales, 1985,
78:7–14.
23. Diallo M et al. Amplification of the sylvatic cycle of dengue virus type 2, Senegal,
1999--2000: entomologic findings and epidemiologic considerations. Emerging
Infectious Diseases (serial online), 2003, March (date cited). Accessible at http://
18 www.cdc.gov/ncidod/EID/vol9no3/02-0219.htm.
31. Chapter 1: Epidemiology, burden of disease and transmission
24. WHO/EMRO. World Health Organization, Regional Office for the Eastern
Mediterranean, Division of Communicable Disease Control, Newsletter, I2005, 6:7–8.
(http://www.emro.who.int/pdf/dcdnewsletter6.pdf).
25. Hyams KC et al. Evaluation of febrile patients in Port Sudan, Sudan: isolation of
dengue virus. American Journal of Tropical Medicine and Hygiene, 1986, 35:860–
865.
CHAPTER 1
26. Rodier GR et al. Epidemic dengue 2 in the city of Djibouti 1991–1992. Transactions
of the Royal Society of Tropical Medicine and Hygiene, 1996, 90:237–240.
27. Bushra J. Dengue Virus Serotype 3, Karachi, Pakistan. Emerging Infectious Diseases,
2007, 13(1).
28. European Centre for Disease Prevention and Control. Dengue worldwide: an
overview of the current situation and implications for Europe, Eurosurveillance, 2007,
12(25). (http://www.eurosurveillance.org/ViewArticle.aspx?PublicationType=WVol
ume=12Issue=25OrderNumber=1).
29. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control,
2nd ed. Geneva, World Health Organization, 1997.
30. Guha-Sapir D, Schimmer B. Dengue fever: new paradigms for a changing
epidemiology. Emerging Themes in Epidemiology, 2005 (Open access journal, http://
www.ete-online.com/content/2/1/1).
31. Deen J et al. The WHO dengue classification and case definitions: time for a
reassessment. Lancet, 2006, 368:170--173.
32. Rigau-Perez J. Severe dengue: the need for new case definitions. Lancet Infectious
Diseases, 2006, 6:297–302.
33. Bandyopadhyay S, Lum LC, Kroeger A. Classifying dengue: a review of the
difficulties in using the WHO case classification for dengue haemorrhagic fever. Tropical
Medicine and International Health, 2006, 11(8):1238--1255.
34. Cattand P et al. Tropical diseases lacking adequate control measures: dengue,
leishmaniasis, and African trypanosomiasis. Disease control priorities in developing
countries, 2nd ed. New York, NY, Oxford University Press, 2006 (pp 451–466).
35. Meltzer MI et al. Using disability-adjusted life years to assess the economic impact
of dengue in Puerto Rico: 1984–1994. American Journal of Tropical Medicine and
Hygiene, 1998, 59:265–271.
36. Suaya JA, Shepard DS, Beatty ME. Dengue burden of disease and costs of illness.
Working paper 3.2 in: Report of the Scientific Working Group meeting on Dengue, Geneva,
1–5 October 2006. Geneva, World Health Organization, Special Programme for Research
and Training in Tropical Diseases, 2007 (pp 35--49) (Document TDR/SWG/07).
19
32. Dengue: Guidelines for diagnosis, treatment, prevention and control
37. Anderson K et al. Burden of symptomatic dengue infection in children at primary
school in Thailand: a prospective study. Lancet, 2007, 369(9571):1452--1459.
38. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LCS, Tan LH, Kongsin S,
Jiamton S, Garrido F, Montoya R, Armien B, Huy R, Castillo L, Caram M, Sah BK,
Sughayyar R, Tyo KR, Halstead SB. Costs of dengue cases in 8 countries in the Americas
and Asia: A prospective study. American Journal of Tropical Medicine and Hygiene,
2009, 80:846--855.
39. Guzman MG. Effect of age on outcome of secondary dengue 2 infections.
International Journal of Infectious Diseases, 2002, 6(2):118--124.
40. Wilder-Smith A, Wilson ME. Sentinel surveillance for dengue: international travellers
(unpublished report).
41. Wilson ME. The traveler and emerging infections: sentinel, courier, transmitter.
Journal of Applied Microbiology, 2003, 94:1S--11S.
42. Schwartz E. Seasonality, annual trends, and characteristics of dengue among ill
returned travelers, 1997–2006. Emerging Infectious Diseases, 2008, 14(7).
43. Leitmeyer KC. Dengue virus structural differences that correlate with pathogenesis.
Journal of Virology, 1999, 73(6):4738--4747.
44. Lanciotti RS et al. Molecular evolution and epidemiology of dengue-3 viruses.
Journal of General Virology, 1994, 75(Pt 1):65--75.
45. Messer WB. Emergence and global spread of a dengue serotype 3, subtype III
virus. Emerging Infectious Diseases, 2003, 9(7):800--809.
46. Halstead SB. Etiologies of the experimental dengues of Siler and Simmons. American
Journal of Tropical Medicine and Hygiene, 1974, 23:974--982.
47. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis
of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and
virus recovered. Yale Journal of Biology and Medicine, 1970, 42:311–328.
48. Sangkawibha N et al. Risk factors in dengue shock syndrome: a prospective
epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. American Journal of
Epidemiology, 1984;120:653--669.
49. Guzman MG et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997.
American Journal of Epidemiology, 2000, 152(9):793--799.
50. Halstead SB. Pathophysiology and pathogenesis of dengue haemorrhagic fever. In:
Thongchareon P, ed. Monograph on dengue/dengue haemorrhagic fever. New Delhi,
World Health Organization, Regional Office for South-East Asia, 1993 (pp 80--103).
20
33. Chapter 1: Epidemiology, burden of disease and transmission
51. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and
hemorrhage: a pathogenetic cascade. Reviews of Infectious Diseases, 1989, 11(Suppl
4):S830--S839.
52. Halstead SB, Heinz FX. Dengue virus: molecular basis of cell entry and pathogenesis,
25-27 June 2003, Vienna, Austria. Vaccine, 2005, 23(7):849--856.
53. Kouri GP, Guzman MG. Dengue haemorrhagic fever/dengue shock syndrome:
CHAPTER 1
lessons from the Cuban epidemic, 1981. Bulletin of the World Health Organization,
1989, 67(4):375--380.
54. Sierra B, Kouri G, Guzman MG. Race: a risk factor for dengue hemorrhagic fever.
Archives of Virology, 2007, 152(3):533--542.
55. Avirutnan P et al. Dengue virus infection of human endothelial cells leads to
chemokine production, complement activation, and apoptosis. Journal of Immunology,
1998, 161:6338--6346.
56. Cardier JE et al. Proinflammatory factors present in sera from patients with acute
dengue infection induce activation and apoptosis of human microvascular endothelial
cells: possible role of TNF-alpha in endothelial cell damage in dengue. Cytokine,
2005, 30(6):359--365.
21
37. Chapter 2: Clinical management and delivery of clinical services
CHAPTER 2. CLINICAL MANAGEMENT AND DELIVERY OF CLINICAL
SERVICES
2.1 OVERVIEW
Dengue infection is a systemic and dynamic disease. It has a wide clinical spectrum
that includes both severe and non-severe clinical manifestations (1). After the incubation
period, the illness begins abruptly and is followed by the three phases -- febrile, critical
and recovery (Figure 2.1).
CHAPTER 2
For a disease that is complex in its manifestations, management is relatively simple,
inexpensive and very effective in saving lives so long as correct and timely interventions
are instituted. The key is early recognition and understanding of the clinical problems
during the different phases of the disease, leading to a rational approach to case
management and a good clinical outcome. An overview of good and bad clinical
practices is given in Textbox A.
Activities (triage and management decisions) at the primary and secondary care levels
(where patients are first seen and evaluated) are critical in determining the clinical
outcome of dengue. A well-managed front-line response not only reduces the number
of unnecessary hospital admissions but also saves the lives of dengue patients. Early
notification of dengue cases seen in primary and secondary care is crucial for identifying
outbreaks and initiating an early response (Chapter 5). Differential diagnosis needs to
be considered (Textbox B).
Figure 2.1 The course of dengue illness*
Days of illness 1 2 3 4 5 6 7 8 9 10
Temperature
40°
Dehydration Shock Reabsorption
Potential clinical issues bleeding fluid overload
Organ impairment
Platelet
Laboratory changes
Hematocrit
IgM/IgG
Serology and virology Viraemia
Course of dengue illness: Febrile Critical Recovery phases 25
* Source: adapted from Yip (2) by chapter authors.
38. Dengue: Guidelines for diagnosis, treatment, prevention and control
2.1.1 Febrile phase
Patients typically develop high-grade fever suddenly. This acute febrile phase usually
lasts 2–7 days and is often accompanied by facial flushing, skin erythema, generalized
body ache, myalgia, arthralgia and headache (1). Some patients may have sore
throat, injected pharynx and conjunctival injection. Anorexia, nausea and vomiting
are common. It can be difficult to distinguish dengue clinically from non-dengue febrile
diseases in the early febrile phase. A positive tourniquet test in this phase increases the
probability of dengue (3,4). In addition, these clinical features are indistinguishable
between severe and non-severe dengue cases. Therefore monitoring for warning signs
and other clinical parameters (Textbox C) is crucial to recognizing progression to the
critical phase.
Mild haemorrhagic manifestations like petechiae and mucosal membrane bleeding
(e.g. nose and gums) may be seen (3,5). Massive vaginal bleeding (in women of
childbearing age) and gastrointestinal bleeding may occur during this phase but is not
common (5). The liver is often enlarged and tender after a few days of fever (3). The
earliest abnormality in the full blood count is a progressive decrease in total white cell
count, which should alert the physician to a high probability of dengue.
2.1.2 Critical phase
Around the time of defervescence, when the temperature drops to 37.5–38oC or less
and remains below this level, usually on days 3–7 of illness, an increase in capillary
permeability in parallel with increasing haematocrit levels may occur (6,7). This marks
the beginning of the critical phase. The period of clinically significant plasma leakage
usually lasts 24–48 hours.
Progressive leukopenia (3) followed by a rapid decrease in platelet count usually precedes
plasma leakage. At this point patients without an increase in capillary permeability will
improve, while those with increased capillary permeability may become worse as a
result of lost plasma volume. The degree of plasma leakage varies. Pleural effusion and
ascites may be clinically detectable depending on the degree of plasma leakage and
the volume of fluid therapy. Hence chest x-ray and abdominal ultrasound can be useful
tools for diagnosis. The degree of increase above the baseline haematocrit often reflects
the severity of plasma leakage.
Shock occurs when a critical volume of plasma is lost through leakage. It is often
preceded by warning signs. The body temperature may be subnormal when shock
occurs. With prolonged shock, the consequent organ hypoperfusion results in progressive
organ impairment, metabolic acidosis and disseminated intravascular coagulation. This
in turn leads to severe haemorrhage causing the haematocrit to decrease in severe
shock. Instead of the leukopenia usually seen during this phase of dengue, the total
white cell count may increase in patients with severe bleeding. In addition, severe organ
impairment such as severe hepatitis, encephalitis or myocarditis and/or severe bleeding
may also develop without obvious plasma leakage or shock (8).
Those who improve after defervescence are said to have non-severe dengue. Some
26 patients progress to the critical phase of plasma leakage without defervescence and, in
39. Chapter 2: Clinical management and delivery of clinical services
these patients, changes in the full blood count should be used to guide the onset of the
critical phase and plasma leakage.
Those who deteriorate will manifest with warning signs. This is called dengue with
warning signs (Textbox C). Cases of dengue with warning signs will probably recover
with early intravenous rehydration. Some cases will deteriorate to severe dengue (see
below).
2.1.3 Recovery phase
CHAPTER 2
If the patient survives the 24–48 hour critical phase, a gradual reabsorption of
extravascular compartment fluid takes place in the following 48–72 hours. General
well-being improves, appetite returns, gastrointestinal symptoms abate, haemodynamic
status stabilizes and diuresis ensues. Some patients may have a rash of “isles of white
in the sea of red” (9). Some may experience generalized pruritus. Bradycardia and
electrocardiographic changes are common during this stage.
The haematocrit stabilizes or may be lower due to the dilutional effect of reabsorbed
fluid. White blood cell count usually starts to rise soon after defervescence but the
recovery of platelet count is typically later than that of white blood cell count.
Respiratory distress from massive pleural effusion and ascites will occur at any time if
excessive intravenous fluids have been administered. During the critical and/or recovery
phases, excessive fluid therapy is associated with pulmonary oedema or congestive
heart failure.
The various clinical problems during the different phases of dengue can be summarized
as in Table 2.1.
Table 2.1 Febrile, critical and recovery phases in dengue
1 Febrile phase Dehydration; high fever may cause neurological disturbances and febrile
seizures in young children
2 Critical phase Shock from plasma leakage; severe haemorrhage; organ impairment
3 Recovery phase Hypervolaemia (only if intravenous fluid therapy has been excessive and/or
has extended into this period)
2.1.4 Severe dengue
Severe dengue is defined by one or more of the following: (i) plasma leakage that may
lead to shock (dengue shock) and/or fluid accumulation, with or without respiratory
distress, and/or (ii) severe bleeding, and/or (iii) severe organ impairment.
As dengue vascular permeability progresses, hypovolaemia worsens and results in
shock. It usually takes place around defervescence, usually on day 4 or 5 (range
days 3–7) of illness, preceded by the warning signs. During the initial stage of shock,
the compensatory mechanism which maintains a normal systolic blood pressure also
produces tachycardia and peripheral vasoconstriction with reduced skin perfusion, 27
40. Dengue: Guidelines for diagnosis, treatment, prevention and control
resulting in cold extremities and delayed capillary refill time. Uniquely, the diastolic
pressure rises towards the systolic pressure and the pulse pressure narrows as the
peripheral vascular resistance increases. Patients in dengue shock often remain conscious
and lucid. The inexperienced physician may measure a normal systolic pressure and
misjudge the critical state of the patient. Finally, there is decompensation and both
pressures disappear abruptly. Prolonged hypotensive shock and hypoxia may lead to
multi-organ failure and an extremely difficult clinical course (Textbox D).
The patient is considered to have shock if the pulse pressure (i.e. the difference between
the systolic and diastolic pressures) is ≤ 20 mm Hg in children or he/she has signs
of poor capillary perfusion (cold extremities, delayed capillary refill, or rapid pulse
rate). In adults, the pulse pressure of ≤ 20 mm Hg may indicate a more severe shock.
Hypotension is usually associated with prolonged shock which is often complicated by
major bleeding.
Patients with severe dengue may have coagulation abnormalities, but these are usually not
sufficient to cause major bleeding. When major bleeding does occur, it is almost always
associated with profound shock since this, in combination with thrombocytopaenia,
hypoxia and acidosis, can lead to multiple organ failure and advanced disseminated
intravascular coagulation. Massive bleeding may occur without prolonged shock in
instances when acetylsalicylic acid (aspirin), ibuprofen or corticosteroids have been
taken.
Unusual manifestations, including acute liver failure and encephalopathy, may be
present, even in the absence of severe plasma leakage or shock. Cardiomyopathy
and encephalitis are also reported in a few dengue cases. However, most deaths from
dengue occur in patients with profound shock, particularly if the situation is complicated
by fluid overload.
Severe dengue should be considered if the patient is from an area of dengue risk
presenting with fever of 2–7 days plus any of the following features:
• There is evidence of plasma leakage, such as:
– high or progressively rising haematocrit;
– pleural effusions or ascites;
– circulatory compromise or shock (tachycardia, cold and clammy extremities,
capillary refill time greater than three seconds, weak or undetectable pulse,
narrow pulse pressure or, in late shock, unrecordable blood pressure).
• There is significant bleeding.
• There is an altered level of consciousness (lethargy or restlessness, coma,
convulsions).
• There is severe gastrointestinal involvement (persistent vomiting, increasing or
intense abdominal pain, jaundice).
• There is severe organ impairment (acute liver failure, acute renal failure,
encephalopathy or encephalitis, or other unusual manifestations, cardiomyopathy)
or other unusual manifestations.
28
41. Chapter 2: Clinical management and delivery of clinical services
2.2 Delivery of clinical services and case management
2.2.1 Introduction
Reducing dengue mortality requires an organized process that guarantees early
recognition of the disease, and its management and referral when necessary. The key
component of the process is the delivery of good clinical services at all levels of health
care, from primary to tertiary levels. Most dengue patients recover without requiring
hospital admission while some may progress to severe disease. Simple but effective
triage principles and management decisions applied at the primary and secondary care
levels, where patients are first seen and evaluated, can help in identifying those at risk
of developing severe disease and needing hospital care. This should be complemented
CHAPTER 2
by prompt and appropriate management of severe dengue in referral centres.
Activities at the first level of care should focus on:
– recognizing that the febrile patient could have dengue;
– notifying early to the public health authorities that the patient is a suspected case
of dengue;
– managing patients in the early febrile phase of dengue;
– recognizing the early stage of plasma leakage or critical phase and initiating
fluid therapy;
– recognizing patients with warning signs who need to be referred for admission
and/or intravenous fluid therapy to a secondary health care facility;
– recognizing and managing severe plasma leakage and shock, severe bleeding
and severe organ impairment promptly and adequately.
2.2.2. Primary and secondary health care centres
At primary and secondary levels, health care facilities are responsible for emergency/
ambulatory triage assessment and treatment.
Triage is the process of rapidly screening patients soon after their arrival in the hospital
or health facility in order to identify those with severe dengue (who require immediate
emergency treatment to avert death), those with warning signs (who should be given
priority while waiting in the queue so that they can be assessed and treated without
delay), and non-urgent cases (who have neither severe dengue nor warning signs).
During the early febrile phase, it is often not possible to predict clinically whether a patient
with dengue will progress to severe disease. Various forms of severe manifestations
may unfold only as the disease progresses through the critical phase, but the warning
signs are good indicators of a higher risk of developing severe dengue. Therefore, the
patient should have daily outpatient health care assessments for disease progression
with careful checking for manifestations of severe dengue and warning signs.
Health care workers at the first levels of care should apply a stepwise approach, as
suggested in Table 2.2. 29